

Tuesday, November 27, 2018

Volume 49 No. 11



NOTICE – Items in this issue will be listed online weekly and printed monthly.

NEW COMPANY DESCRIPTIONS

(For details on individual listings, see the News Section of this issue)

Spring Pharmaceutical Group Inc

ACACIA COMMUNICATIONS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	232,758	298,563
Cost & expenses	251,536	266,453
Operating income	(18,778)	32,110
Other income (expense), net	(325)	(60)
Net before taxes	(14,184)	34,312
Income taxes	(10,012)	(24,560)
Net income	(4,172)	58,872
Earnings common share		
Primary	\$(0.10)	\$1.52
Fully Diluted	\$(0.10)	\$1.41
Common Shares:		
Full Diluted	40,217	41,660
Year-end	40,405	39,302

ADVANCED ENERGY INDUSTRIES INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	564,731	491,798
Cost & expenses	408,790	345,914
Operating income	151,983	142,708
Other income (expense), net	(58)	(3,138)
Net before taxes	151,925	139,570
Income taxes	23,998	(25,538)
Income contin. oper.	127,927	165,108
Income discont. oper.	(226)	2,343
Net income	127,701	167,451
Earnings common share		
Primary	\$3.25	\$4.21
Fully Diluted	\$3.23	\$4.16
Common Shares:		
Full Diluted	39,594	40,207
Year-end	38,716	39,624

AEVI GENOMIC MEDICINE INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	24,285	27,540
Operating income	(24,285)	(27,540)
Other income (expense), net	136	(15)
Net income	(24,149)	(27,555)
Earnings common share		
Primary	\$(0.40)	\$(0.74)
Fully Diluted	\$(0.40)	\$(0.74)
Common Shares:		
Full Diluted	60,241	37,109
Year-end	64,767	37,110

AGILYSYS INC

Earnings, 6 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	68,210	63,994
Cost & expenses	71,154	67,949
Operating income	(5,443)	(6,217)
Interest income	152	51
Interest expense	5	4
Other income (expense), net	(228)	147
Net before taxes	(5,524)	(6,023)
Income taxes	4	183
Net income	(5,528)	(6,206)
Earnings common share		
Primary	\$(0.24)	\$(0.27)
Fully Diluted	\$(0.24)	\$(0.27)

Common Shares:

Full Diluted	23,113	22,740
Year-end	23,531	23,318

AGIOS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	64,374	33,212
Cost & expenses	330,497	263,876
Operating income	(266,123)	(230,664)
Interest income	11,889	4,279
Net income	(254,234)	(226,385)
Earnings common share		
Primary	\$(4.45)	\$(4.94)
Fully Diluted	\$(4.45)	\$(4.94)
Common Shares:		
Full Diluted	57,158	45,851
Year-end	58,168	48,618

AIR TRANSPORT SERVICES GROUP, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	611,566	745,229
Cost & expenses	408,373	567,894
Deprec., depl. & amort.	124,825	111,828
Operating income	78,368	65,507
Interest income	144	85
Interest expense	16,336	11,658
Other income (expense), net	27,242	(107,041)
Net before taxes	89,418	(53,107)
Income taxes	16,339	19,244
Income contin. oper.	73,079	(72,351)
Net income	73,615	(76,622)
Earnings common share		
Primary	\$1.25	\$(1.30)
Fully Diluted	\$0.72	\$(1.30)
Common Shares:		
Full Diluted	68,629	58,965
Year-end	59,080	59,123

ALLEGIANT TRAVEL COMPANY

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,255,333	1,132,049
Cost & expenses	982,321	835,612
Deprec., depl. & amort.	92,641	92,571
Operating income	180,371	203,866
Other income (expense), net	408	1,254
Net before taxes	146,850	181,981
Income taxes	26,494	67,208
Net income	120,356	114,773
Balance for common		
Primary	\$7.46	\$7.00
Fully Diluted	\$7.45	\$6.99
Common Shares:		
Full Diluted	15,938	16,160
Year-end	16,160	16,160

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	1,561,782,000	289,008,000
Cost & expenses	1,585,279,000	207,928,000
Operating income	(60,707,000)	57,740,000
Interest expense	80,843,000	62,722,000
Other income (expense), net	(16,077,000)	165,835,000
Gains or losses	172,787,000	706,000
Net before taxes	15,160,000	170,111,000

Income taxes	(3,020,000)	(1,073,000)
Income contin. oper.	18,180,000	
Net income	21,911,000	169,038,000
Balance for common		
Primary	(11,041,000)	202,277,000

Earnings common share

Primary	\$(0.06)	\$(1.12)
Fully Diluted	\$(0.06)	\$(1.12)

Common Shares:

Full Diluted	176,942,000	180,864,000
Year-end	174,707,000	

AMAG PHARMACEUTICALS, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	385,881	367,243
Cost & expenses	414,091	658,355
Operating income	(28,210)	(291,112)
Interest expense	45,400	52,403
Other income (expense), net	(35,985)	(9,873)
Net before taxes	(106,388)	(351,207)
Income taxes	42,204	(145,317)
Income contin. oper.	(148,592)	(205,890)
Income discont. oper.	105,108	3,202
Net income	(43,484)	(202,688)
Earnings common share		
Primary	\$(1.27)	\$(5.80)
Fully Diluted	\$(1.27)	\$(5.80)
Common Shares:		
Full Diluted	34,339	34,948
Year-end	34,523	

AMC NETWORKS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	2,199,083	2,078,757
Cost & expenses	1,545,264	1,452,905
Operating income	589,785	560,815
Interest income	15,453	10,841
Interest expense	115,607	96,609
Other income (expense), net	30,989	39,444
Net before taxes	520,620	514,491
Income taxes	133,092	173,399
Net income	387,528	341,092
Earnings common share		
Primary	\$6.40	\$4.94
Fully Diluted	\$6.31	\$4.89
Common Shares:		
Full Diluted	59,281	66,651
Year-end	56,509	62,713

APPIAN CORP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	166,527	126,175
Cost & expenses	199,944	151,031
Operating income	(33,417)	(24,856)
Other income (expense), net	(1,785)	1,658
Net before taxes	(35,336)	(23,649)
Income taxes	212	489
Net income	(35,548)	(24,138)
Balance for common		
Primary	(35,548)	(24,495)
Earnings common share		
Primary	\$(0.58)	\$(0.53)
Fully Diluted	\$(0.58)	\$(0.53)
Common Shares:		
Full Diluted	61,584	45,855
Year-end	63,588	60,277

APPTIO INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	172,338	136,152
Cost & expenses	187,159	154,671
Operating income	(14,821)	(18,519)
Interest income	2,375	859
Interest expense	4,021	21
Other income (expense), net	81	(27)
Foreign currency	(797)	159
Net before taxes	(17,183)	(17,549)
Income taxes	783	614
Net income	(17,966)	(18,163)
Balance for common	(17,966)	(18,163)
Earnings common share		
Primary	\$(0.41)	\$(0.46)
Fully Diluted	\$(0.41)	\$(0.46)
Common Shares:		
Full Diluted	43,830	39,240
Year-end	45,081	

APPTIO INC

Sale Development On Nov. 12, 2018, Co. announced that it agreed to be bought by private equity firm Vista Equity Partners for \$1,940,000,000 in cash. Co.'s board has approved the deal, which is expected to close in the first quarter of 2019.

ARATANA THERAPEUTICS, INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	30,506	15,116
Cost & expenses	34,286	44,489
Operating income	(4,168)	(29,608)
Interest income	441	311
Interest expense	2,357	2,601
Other income (expense), net	(4)	(14)
Net income	(6,088)	(31,912)
Earnings common share		
Primary	\$(0.13)	\$(0.80)
Fully Diluted	\$(0.13)	\$(0.80)
Common Shares:		
Full Diluted	46,128	39,821
Year-end	47,981	42,461

ARCHROCK PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	451,901	415,741
Cost & expenses	315,550	306,878
Deprec., depl. & amort.	102,319	108,947
Operating income	34,032	(84)
Net before taxes	34,032	(84)
Income taxes	648	2,970
Net income	33,384	(3,054)
Earnings common share		
Fully Diluted	66,298	71,608
Common Shares:		
Full Diluted	71,653	

ATHENAHEALTH INC

Sale Development On Nov. 12, 2018, Co. announced that it will be acquired by private equity firm Veritas Capital and hedge fund Elliott Management for about \$5,700,000,000 in cash. The transaction is expected to close in the first quarter of 2019.

ATLAS AIR WORLDWIDE HOLDINGS, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,912,766	1,528,508
Cost & expenses	1,600,900	1,272,369
Operating income	155,985	135,226
Interest income	4,704	4,286
Other income (expense), net	(914)	(36,035)
Net before taxes	76,471	36,363
Income taxes	16,828	21,479
Income contin. oper.	59,643	14,884
Net income	59,593	14,025
Earnings common share		
Primary	\$2.33	\$0.56
Fully Diluted	\$2.27	\$0.54
Common Shares:		
Full Diluted	26,274	25,822
Year-end	25,590	25,283

AXCELIS TECHNOLOGIES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	336,892	294,165
Cost & expenses	288,455	257,087
Operating income	48,437	37,078
Interest income	1,518	399
Interest expense	3,787	3,784
Other income (expense), net	(1,710)	
Net before taxes	44,458	33,693
Income taxes	7,036	(1,586)
Net income	37,422	35,279
Earnings common share		
Primary	\$1.16	\$1.15
Fully Diluted	\$1.10	\$1.07
Common Shares:		
Full Diluted	34,032	33,048
Year-end	32,398	31,433

BANDWIDTH INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	151,770	120,489
Cost & expenses	141,748	108,083
Operating income	10,022	12,406
Other income (expense), net	242	(1,950)
Net before taxes	10,264	10,456
Income taxes	(8,949)	3,886
Net income	19,213	6,570
Balance for common	19,213	5,712
Earnings common share		
Primary	\$1.05	\$0.48
Fully Diluted	\$0.91	\$0.42
Common Shares:		
Full Diluted	21,066	13,488
Year-end	19,349	17,621

BLACK BOX CORP. (DE)

Merger Development On Nov. 11, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with AGC Networks Pte Ltd. ("Top Parent"), a company organized under the laws of Singapore which operates as an information, communications, and technology solutions provider and integrator worldwide, BBX Main Inc. ("Parent"), a wholly-owned subsidiary of Top Parent, BBX Inc. ("BBX Intermediate"), a wholly-owned subsidiary of Parent, and Host Merger Sub Inc., a wholly-owned subsidiary of BBX Intermediate ("Merger Sub"), and, together with Top Parent, Parent and BBX Intermediate, the "Parent Entities" and each, a "Parent Entity"). Pursuant to the terms of the Merger Agreement, Top Parent, Parent and BBX Intermediate have agreed to cause Merger Sub to commence a tender offer (as it may be extended, amended or supplemented from time to time, the "Offer") to purchase any and all of the outstanding shares of common stock, par value \$0.001 per share, of Co. (the "Shares"), at a price of \$1.08 per Share, net to the holder thereof, in cash, without interest thereon (such amount, the "Offer Price"). Following the consummation of the Offer, Merger Sub will merge with and into Co. (the "Merger") in accordance with the General Corporation Law of the State of Delaware (the "DGCL") and Section 251(h) thereof. Each Share that is not tendered and accepted pursuant to the Offer (other than Shares owned by BBX Intermediate, Merger Sub or Co., or by any of their direct or indirect wholly-owned subsidiaries, and Shares held by stockholders of Co. who are entitled to demand and who will have properly and validly demanded their statutory rights of appraisal in compliance in all respects with Section 262 of the DGCL) will be automatically converted into the right to receive the Offer Price at the time of the Merger (such time, the "Effective Time"), and Co. will survive the Merger as a wholly-owned subsidiary of BBX Intermediate, all upon the terms and subject to the conditions set forth in the Merger Agreement. The transaction is expected to close prior to the end of the calendar year.

BLACKBAUD, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	627,388	571,085
Cost & expenses	578,943	520,702
Operating income	44,738	48,219
Interest expense	11,960	8,685
Other income (expense), net	(1,254)	338
Gains or losses		472
Net before taxes	33,137	41,115
Income taxes	(2,370)	4,120
Net income	35,507	36,995
Earnings common share		
Primary	\$0.75	\$0.76

	2018	2017
Fully Diluted	\$0.74	\$0.74
Common Shares:		
Full Diluted	48,075	47,679
Year-end	48,567	48,078

BLOOMIN' BRANDS INC

Earnings, 9 mos. to (Consol. - \$000):

	09/30/18	09/24/17
Total Revenues	3,113,300	3,146,756
Cost & expenses	2,837,995	2,880,882
Operating income	123,832	123,395
Interest expense	33,229	29,389
Other income (expense), net	(6)	14,501
Net before taxes	90,597	108,507
Income taxes	(6,516)	17,744
Net income	97,113	90,763
Earnings common share		
Primary	\$1.04	\$0.91
Fully Diluted	\$1.02	\$0.88
Common Shares:		
Full Diluted	94,489	101,497
Year-end	91,854	91,164

BLUCORA, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	459,198,000	411,708,000
Cost & expenses	348,937,000	321,278,000
Operating income	81,171,000	62,558,000
Interest income	217,000	76,000
Other income (expense), net	364,000	(21,588,000)
Net before taxes	69,321,000	23,409,000
Income taxes	2,052,000	5,952,000
Net income	67,269,000	17,457,000
Balance for common	63,078,000	16,991,000
Earnings common share		
Primary	\$1.34	\$0.39
Fully Diluted	\$1.28	\$0.36
Common Shares:		
Full Diluted	49,292,000	46,813,000
Year-end	47,816,000	46,077,000

BLUEBIRD BIO INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	35,336	31,259
Cost & expenses	450,398	246,652
Operating income	(415,062)	(215,393)
Other income (expense), net	45	(1,180)
Net income	(406,602)	(218,415)
Earnings common share		
Primary	\$(7.95)	\$(5.14)
Fully Diluted	\$(7.95)	\$(5.14)
Common Shares:		
Full Diluted	51,130	42,524
Year-end	54,678	

BMC STOCK HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	2,822,927	2,525,087
Cost & expenses	2,652,804	2,404,302
Operating income	129,537	76,283
Interest expense	17,916	18,960
Other income (expense), net	7,830	2,366
Net before taxes	119,451	59,689
Income taxes	27,829	19,906
Net income	91,622	39,783
Earnings common share		
Primary	\$1.36	\$0.60
Fully Diluted	\$1.35	\$0.59
Common Shares:		
Full Diluted	67,743	67,341
Year-end	67,300	66,900

BRIGHTCOVE INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	123,969	115,812
Cost & expenses	134,543	134,177
Operating income	(10,574)	(18,365)
Interest expense	5	22
Other income (expense), net	(579)	453
Net before taxes	(11,001)	(17,842)

Income taxes	410	305
Net income	(11,411)	(18,147)
Earnings common share		
Primary	\$(0.32)	\$(0.53)
Fully Diluted	\$(0.32)	\$(0.53)
Common Shares:		
Full Diluted	35,564	34,270
Year-end	36,469	34,622

BUILDERS FIRSTSOURCE INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	5,908,791	5,255,270
Cost & expenses	5,630,300	5,034,968
Operating income	278,491	220,302
Interest expense	84,805	103,703
Net before taxes	193,686	116,599
Income taxes	40,516	35,117
Net income	153,170	81,482
Earnings common share		
Primary	\$1.34	\$0.73
Fully Diluted	\$1.31	\$0.71
Common Shares:		
Full Diluted	116,614	115,310
Year-end	114,725	112,931

CASELLA WASTE SYSTEMS, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	485,936,000	448,087,000
Cost & expenses	389,493,000	424,217,000
Deprec., depl. & amort.	51,572,000	46,307,000
Operating income	44,871,000	(22,437,000)
Interest income	161,000	180,000
Other income (expense), net	(6,755,000)	50,000
Net before taxes	18,930,000	(41,259,000)
Income taxes	(1,166,000)	561,000
Net income	20,096,000	(41,820,000)
Earnings common share		
Primary	\$0.47	\$(1.00)
Fully Diluted	\$0.46	\$(1.00)
Common Shares:		
Full Diluted	43,938,000	41,783,000
Year-end	42,920,000	42,043,000

CDW CORP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	12,165,700	11,080,800
Cost & expenses	11,421,300	10,435,200
Operating income	744,400	645,600
Interest expense	111,500	113,400
Other income (expense), net	1,000	(55,500)
Net before taxes	633,900	476,700
Income taxes	150,200	148,400
Net income	483,700	328,300
Earnings common share		
Primary	\$3.19	\$2.10
Fully Diluted	\$3.14	\$2.06
Common Shares:		
Full Diluted	154,100	159,200
Year-end	150,900	152,900

CENTURY ALUMINUM CO.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	1,406,300	1,155,200
Cost & expenses	1,396,900	1,104,600
Operating income	9,400	50,600
Other income (expense), net	1,800	(1,000)
Gains or losses	2,800	(17,100)
Equity earnings	(3,200)	(500)
Net before taxes	(1,400)	16,800
Income taxes	3,000	4,500
Net income	(1,200)	12,800
Earnings common share		
Primary	\$(0.01)	\$0.13
Fully Diluted	\$(0.01)	\$0.13
Common Shares:		
Full Diluted	87,600	88,100
Year-end	87,608	

CHEMIBIO DIAGNOSTICS INC

Acquisition Completed On Nov. 6, 2018, Co. acquired all the outstanding equity shares of opTricon GmbH ("opTricon"), a developer and manufacturer of handheld analyzers for rapid diagnostic tests, for \$5,500,000 in cash, of which (a) \$100,000 was deposited in escrow for a potential purchase price adjustment based on the working capital of opTricon and (b) \$750,000 was deposited in escrow to satisfy certain claims that Co. may make against the sellers in accordance with the terms of the Purchase Agreement.

CHURCHILL DOWNS, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	790,000,000	703,700,000
Cost & expenses	613,200,000	545,300,000
Operating income	176,800,000	158,400,000
Other income (expense), net	24,900,000	23,500,000
Gains or losses	54,900,000	
Net before taxes	227,400,000	145,900,000
Income taxes	52,100,000	57,900,000
Income contin. oper.	175,300,000	88,000,000
Net income	341,400,000	102,300,000
Balance for common	341,400,000	102,300,000
Earnings common share		
Primary	\$24.64	\$6.43
Fully Diluted	\$24.50	\$6.32
Common Shares:		
Full Diluted	13,900,000	16,200,000
Year-end	13,600,000	

CIRRUS LOGIC INC

Earnings, 6 mos. to (Consol. – \$000):

	09/29/18	09/23/17
Net Sales	620,788	746,272
Cost & expenses	571,367	608,084
Operating income	49,421	138,188
Interest expense	539	615
Other income (expense), net	(168)	(1,135)
Net before taxes	52,225	138,372
Income taxes	(1,676)	22,160
Net income	53,901	116,212
Earnings common share		
Primary	\$0.88	\$1.82
Fully Diluted	\$0.86	\$1.74
Common Shares:		
Full Diluted	62,810	66,761
Year-end	59,844	63,665

CLOVIS ONCOLOGY INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	301,885	212,898
Operating income	(236,848)	(174,427)
Interest expense	9,592	7,796
Other income (expense), net	(22,556)	(114,763)
Foreign currency	(34)	(127)
Net before taxes	(269,030)	(297,113)
Income taxes	(280)	(2,599)
Net income	(268,750)	(294,514)
Earnings common share		
Primary	\$(5.18)	\$(6.39)
Fully Diluted	\$(5.18)	\$(6.39)
Common Shares:		
Full Diluted	51,844	46,062
Year-end	52,709	49,002

COGENT COMMUNICATIONS HOLDINGS, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	263,614	247,984
Operating income	64,250	55,382
Net before taxes	30,520	22,639
Income taxes	8,953	10,536
Net income	21,567	12,103
Earnings common share		
Primary	\$0.48	\$0.27
Fully Diluted	\$0.47	\$0.27
Common Shares:		
Full Diluted	45,591	45,084
Year-end	46,461	45,946

CONCERT PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	10,492	143,879
Cost & expenses	46,013	38,493
Operating income	(35,521)	105,386
Other income (expense), net	(1,359)	(1,432)
Gains or losses	2,003	742
Net before taxes	(34,877)	103,882
Income taxes	298	2,177
Net income	(35,175)	101,705
Balance for common	(35,175)	101,272
Earnings common share		
Primary	\$(1.51)	\$4.49
Fully Diluted	\$(1.51)	\$4.37
Common Shares:		
Full Diluted	23,349	23,195
Year-end	23,428	22,751

	2018	2017
Total Revenues	10,492	143,879
Cost & expenses	46,013	38,493
Operating income	(35,521)	105,386
Other income (expense), net	(1,359)	(1,432)
Gains or losses	2,003	742
Net before taxes	(34,877)	103,882
Income taxes	298	2,177
Net income	(35,175)	101,705
Balance for common	(35,175)	101,272
Earnings common share		
Primary	\$(1.51)	\$4.49
Fully Diluted	\$(1.51)	\$4.37
Common Shares:		
Full Diluted	23,349	23,195
Year-end	23,428	22,751

CONMED CORP.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	617,191	573,837
Cost & expenses	571,709	550,078
Operating income	45,482	23,759
Net before taxes	30,359	10,436
Income taxes	5,158	1,645
Net income	25,201	8,791
Earnings common share		
Primary	\$0.90	\$0.31
Fully Diluted	\$0.87	\$0.31
Common Shares:		
Full Diluted	28,872	28,124
Year-end	28,123	27,927

CONNECTONE BANCORP INC (NEW)

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	113,827	91,491
Operating income	48,824	45,248
Net before taxes	48,824	45,248
Income taxes	7,144	12,608
Net income	41,680	32,640
Earnings common share		
Primary	\$1.30	\$1.02
Fully Diluted	\$1.29	\$1.01
Common Shares:		
Full Diluted	32,313	32,167
Year-end	32,240	32,015

CONSOLIDATED COMMUNICATIONS HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,054,324	703,214
Cost & expenses	711,269	484,190
Deprec., depl. & amort.	328,759	187,084
Operating income	14,296	31,940
Other income (expense), net	1,961	301
Gains or losses	28,999	23,068
Net before taxes	(53,823)	(44,587)
Income taxes	(17,250)	(9,862)
Net income	(36,573)	(34,725)
Balance for common	(37,518)	(35,152)
Earnings common share		
Primary	\$(0.53)	\$(0.62)
Fully Diluted	\$(0.53)	\$(0.62)
Common Shares:		
Full Diluted	70,598	56,955
Year-end	71,253	70,836

CONTROL4 CORP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	199,971	176,043
Cost & expenses	186,497	169,313
Operating income	13,474	6,730
Interest income	819	224
Other income (expense), net	(864)	183
Net before taxes	13,429	7,137
Income taxes	112	(2,459)
Net income	13,317	9,596
Earnings common share		
Primary	\$0.51	\$0.39
Fully Diluted	\$0.48	\$0.36
Common Shares:		
Full Diluted	27,489	26,393
Year-end	26,707	

CORVEL CORP

Earnings, 6 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	298,574,000	274,043,000
Cost & expenses	266,762,000	247,807,000
Operating income	31,812,000	26,236,000
Net before taxes	31,812,000	26,236,000
Income taxes	7,245,000	9,068,000
Net income	24,567,000	17,168,000
Earnings common share		
Primary	\$1.30	\$0.91
Fully Diluted	\$1.29	\$0.90
Common Shares:		
Full Diluted	19,095,000	18,983,000
Year-end	18,826,375	18,824,953

CORVUS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Cost & expenses	38,051	44,335
Operating income	(38,051)	(44,335)
Net income	(36,430)	(43,734)
Earnings common share		
Primary	\$(1.35)	\$(2.14)
Fully Diluted	\$(1.35)	\$(2.14)
Common Shares:		
Full Diluted	26,906	20,426
Year-end	29,282	20,944

COWEN INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	706,985	454,331
Cost & expenses	698,171	494,507
Operating income	(28,478)	(70,697)
Other income (expense), net	(556)	
Gains or losses	123,270	124,606
Foreign currency	250	(299)
Net before taxes	94,792	53,909
Income taxes	15,999	3,407
Net income	78,793	50,502
Balance for common	32,646	9,996
Earnings common share		
Primary	\$1.10	\$0.34
Fully Diluted	\$1.07	\$0.33
Common Shares:		
Full Diluted	30,613	30,011
Year-end	29,143	31,087

CRA INTERNATIONAL INC

Earnings, 9 mos. to (Consol. – \$000):	09/29/18	09/30/17
Total Revenues	308,885	273,059
Cost & expenses	280,495	250,001
Deprec., depl. & amort.	7,300	6,652
Operating income	21,090	16,406
Other income (expense), net	72	(233)
Gains or losses		250
Net before taxes	20,602	16,062
Net income	15,633	9,962
Balance for common	15,551	9,814
Earnings common share		
Primary	\$1.91	\$1.18
Fully Diluted	\$1.81	\$1.15
Common Shares:		
Full Diluted	8,615	8,530
Year-end	8,297	8,056

CROSS COUNTRY HEALTHCARE INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Cost & expenses	595,578	619,978
Operating income	11,235	18,071
Interest expense	4,225	2,975
Other income (expense), net	333	(4,853)
Gains or losses		1,581
Net before taxes	7,343	11,824
Income taxes	3,717	1,278
Net income	3,626	10,546
Balance for common	2,740	9,563
Earnings common share		
Primary	\$0.08	\$0.28
Fully Diluted	\$0.08	\$0.24
Common Shares:		

Full Diluted	35,881	36,179
Year-end	36,251	35,758

CURIS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	7,673	6,636
Cost & expenses	31,432	48,939
Operating income	(24,185)	(42,632)
Other income (expense), net		(104)
Net income	(26,634)	(45,289)
Earnings common share		
Primary	\$(0.80)	\$(1.57)
Fully Diluted	\$(0.80)	\$(1.57)
Common Shares:		
Full Diluted	33,117	28,824
Year-end	33,113	28,469

CYPRESS SEMICONDUCTOR CORP.

Earnings, 9 mos. to (Consol. – \$000):	09/30/18	10/01/17
Total Revenues	1,879,366	1,730,224
Cost & expenses	1,717,678	1,693,825
Operating income	161,688	36,399
Other income (expense), net	4,203	4,800
Equity earnings	10,873	14,842
Net before taxes	114,332	(17,986)
Income taxes	15,829	13,930
Net income	87,630	(46,758)
Earnings common share		
Primary	\$0.24	\$(0.14)
Fully Diluted	\$0.23	\$(0.14)
Common Shares:		
Full Diluted	373,064	329,787
Year-end	361,665	

CYRUSONE INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	600,100	491,500
Cost & expenses	289,000	303,200
Operating income	74,900	200
Interest expense	69,400	48,000
Other income (expense), net	103,500	(36,500)
Net before taxes	109,000	(84,300)
Income taxes	2,000	2,000
Net income	107,000	(86,300)
Balance for common	106,200	(87,000)
Earnings common share		
Primary	\$1.09	\$(0.99)
Fully Diluted	\$1.08	\$(0.99)
Common Shares:		
Full Diluted	98,400	87,500
Year-end	105,834	91,289

DAWSON GEOPHYSICAL CO (NEW)

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	126,486,000	119,114,000
Cost & expenses	116,454,000	121,306,000
Operating income	(13,165,000)	(31,942,000)
Other income (expense), net	172,000	136,000
Net before taxes	(12,980,000)	(31,637,000)
Income taxes	(389,000)	(4,635,000)
Net income	(12,591,000)	(27,002,000)
Earnings common share		
Primary	\$(0.55)	\$(1.19)
Fully Diluted	\$(0.55)	\$(1.19)
Common Shares:		
Full Diluted	22,901,558	22,765,548
Year-end	22,943,639	

DIGIMARC CORP

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	15,965	20,355
Cost & expenses	41,227	38,258
Operating income	(25,262)	(17,903)
Other income (expense), net	799	408
Net before taxes	(24,463)	(17,495)
Income taxes	29	(94)
Net income	(24,492)	(17,401)
Balance for common	(24,492)	(17,401)
Earnings common share		

Primary	\$(2.16)	\$(1.67)
Fully Diluted	\$(2.16)	\$(1.67)
Common Shares:		
Full Diluted	11,333	10,410
Year-end	11,888	11,324

EDGE THERAPEUTICS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Cost & expenses	37,053,686	35,843,480
Operating income	(37,053,686)	(35,843,480)
Interest income	696,035	479,297
Interest expense	1,425,255	1,591,998
Net income	(37,782,906)	(36,956,181)
Earnings common share		
Primary	\$(1.21)	\$(1.23)
Fully Diluted	\$(1.21)	\$(1.23)
Common Shares:		
Full Diluted	31,198,804	30,091,640
Year-end	31,328,128	30,859,200

EL POLLO LOCO HOLDINGS INC

Earnings, 9 mos. to (Consol. – \$000):	09/26/18	09/27/17
Total Revenues	329,567	306,499
Cost & expenses	294,975	276,364
Operating income	21,529	16,489
Interest income	29	17
Interest expense	2,717	2,488
Other income (expense), net	777	(107)
Net before taxes	19,618	13,911
Income taxes	5,202	5,254
Net income	14,416	8,657
Earnings common share		
Primary	\$0.37	\$0.23
Fully Diluted	\$0.37	\$0.22
Common Shares:		
Full Diluted	39,102	39,101
Year-end	39,067	38,653

ENDURANCE INTERNATIONAL GROUP HOLDINGS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	862,896	882,617
Cost & expenses	751,101	857,446
Operating income	111,795	25,171
Interest expense	111,923	121,022
Other income (expense), net		(600)
Equity earnings	2	(72)
Net before taxes	592	(95,945)
Income taxes	8,826	11,384
Net income	(8,236)	(107,257)
Earnings common share		
Primary	\$(0.06)	\$(0.84)
Fully Diluted	\$(0.06)	\$(0.84)
Common Shares:		
Full Diluted	141,947	136,688
Year-end	143,306	

ENSIGN GROUP INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	1,502,884	1,361,612
Cost & expenses	1,373,698	1,273,758
Operating income	94,041	55,142
Interest income	1,477	973
Interest expense	11,471	10,017
Net before taxes	84,047	46,098
Income taxes	18,078	16,487
Net income	65,969	29,611
Earnings common share		
Primary	\$1.27	\$0.58
Fully Diluted	\$1.22	\$0.56
Common Shares:		
Full Diluted	54,176	52,674
Year-end	52,248	51,082

ENTEGRIS INC

Earnings, 9 mos. to (Consol. – \$000):	09/29/18	09/30/17
Net Sales	1,148,855	991,970
Cost & expenses	882,372	788,302
Operating income	221,381	170,665
Interest income	2,613	323

Interest expense	24,442	24,418
Other income (expense), net	(4,826)	(3,762)
Net before taxes	194,726	142,808
Income taxes	34,755	29,401
Net income	159,971	113,407
Earnings common share		
Primary	\$1.13	\$0.80
Fully Diluted	\$1.12	\$0.79
Common Shares:		
Full Diluted	143,308	143,472
Year-end	141,607	141,474

ESSENDANT INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	3,788,907	3,839,018
Cost & expenses	3,835,369	4,090,070
Operating income	(46,462)	(251,052)
Net before taxes	(72,213)	(272,377)
Income taxes	(16,181)	(6,943)
Net income	(56,032)	(265,434)
Earnings common share		
Primary	\$(1.52)	\$(7.23)
Fully Diluted	\$(1.52)	\$(7.23)
Common Shares:		
Full Diluted	36,940	36,692
Year-end	37,643	37,616

EURONET WORLDWIDE INC.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	1,887,244	1,647,777
Cost & expenses	1,521,765	1,353,379
Deprec., depl. & amort.	78,726	69,520
Operating income	286,753	224,878
Interest income	1,000	2,009
Interest expense	28,936	25,058
Other income (expense), net	(117)	
Gains or losses	26	35
Foreign currency	(21,459)	21,035
Net before taxes	237,267	222,899
Income taxes	65,031	43,130
Net income	172,236	179,769
Earnings common share		
Primary	\$3.36	\$3.43
Fully Diluted	\$3.17	\$3.23
Common Shares:		
Full Diluted	54,521	55,583
Year-end	51,459	

EVELO BIOSCIENCES INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	42,110	19,464
Operating income	(42,110)	(19,464)
Other income (expense), net	(406)	(224)
Net income	(41,503)	(19,904)
Balance for common	(45,440)	(24,259)
Earnings common share		
Primary	\$(2.45)	\$(6.52)
Fully Diluted	\$(2.45)	\$(6.52)
Common Shares:		
Full Diluted	18,532	3,722
Year-end	31,758	

EXTREME NETWORKS INC**Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	239,886	211,715
Cost & expenses	242,763	205,609
Operating income	(5,018)	4,492
Interest income	394	647
Interest expense	3,526	2,215
Other income (expense), net	487	3,127
Net before taxes	(7,663)	6,051
Income taxes	1,402	1,675
Net income	(9,065)	4,376
Earnings common share		
Primary	\$(0.08)	\$0.04
Fully Diluted	\$(0.08)	\$0.04
Common Shares:		
Full Diluted	117,368	118,431
Year-end	118,270	113,305

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	140,167	
Inventories	55,580	
Current assets	395,801	
Net property & equip.	76,224	
Total assets	731,884	
Liabilities:		
Current liabilities	322,040	
Long-term debt	176,498	
Stockholders' equity	117,131	
Net current assets	73,761	

FARO TECHNOLOGIES INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Net Sales	290,783,000	254,494,000
Cost & expenses	277,408,000	246,248,000
Deprec., depl. & amort.	13,467,000	12,075,000
Operating income	(92,000)	(3,829,000)
Other income (expense), net	(868,000)	(320,000)
Net before taxes	(755,000)	(3,900,000)
Income taxes	73,000	(442,000)
Net income	(828,000)	(3,458,000)
Earnings common share		
Primary	\$(0.05)	\$(0.21)
Fully Diluted	\$(0.05)	\$(0.21)
Common Shares:		
Full Diluted	16,976,459	16,697,729
Year-end	17,252,160	16,711,152

FATE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	53,430	32,960
Operating income	(50,351)	(29,881)
Interest income	1,046	400
Interest expense	1,266	856
Other income (expense), net		(118)
Net income	(50,571)	(30,455)
Earnings common share		
Primary	\$(0.95)	\$(0.74)
Fully Diluted	\$(0.95)	\$(0.74)
Common Shares:		
Full Diluted	53,365	41,408
Year-end	64,503	

FIDUS INVESTMENT CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Cost & expenses	30,373,000	25,528,000
Operating income	23,844,000	26,019,000
Net before taxes	23,844,000	26,019,000
Income taxes	28,000	29,000
Net income	23,816,000	25,990,000
Earnings common share		
Primary	\$0.97	\$1.12
Fully Diluted	\$0.97	\$1.12
Common Shares:		
Full Diluted	24,474,632	23,201,533
Year-end	24,463,119	24,492,880

FINISAR CORP

Merger Development On Nov. 8, 2018, Co., II-VI Inc. ("Parent") and Mutation Merger Sub Inc. ("Merger Subsidiary"), a wholly-owned subsidiary of Parent, entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other things, Merger Subsidiary will be merged with and into Co. (the "Merger"), with Co. surviving the Merger as a wholly-owned subsidiary of Parent. At the time the Merger becomes effective (the "Effective Time"), each issued and outstanding share of common stock, par value \$0.001 per share, of Co. ("Co. Stock") (other than shares of Co. Stock owned by Parent or Merger Subsidiary or any direct or indirect wholly owned subsidiary of Parent, which will be cancelled without consideration, and holders of Co. Stock, if any, who properly exercise their appraisal rights under the General Corporation Law of the State of Delaware) outstanding immediately prior to the Merger will be automatically cancelled and converted into the right to receive, for each share of Co. Stock, at the stockholder's election and subject to proration in the event the cash consideration or Parent Common Stock (as defined below) consideration is oversubscribed, either (i) \$26.00 in cash (the "Cash Election Consideration"), (ii) 0.5546 of a share of common stock, no par value, of Parent ("Parent Common Stock") (the "Stock Election Consideration"), or (iii)

a combination of (A) 0.2218 of a share of Parent Common Stock (the "Exchange Ratio") and (B) \$15.60 in cash, without interest (the "Mixed Election Consideration"). On an average basis across all shares of Co. Stock (including the Options (as defined below) and Performance RSUs (as defined below)), at the closing of the Merger, 60% of the aggregate amount of the outstanding shares of Co. Stock (including the Options and Performance RSUs) will be converted into the right to receive the Cash Election Consideration, with the remaining 40% converted into the right to receive the Stock Election Consideration. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase Co. Stock (whether vested or unvested) (an "Option") shall automatically be cancelled and terminated and converted into the right to receive an amount of Mixed Election Consideration equal to the product of (i) the excess, if any, of the Cash Election Consideration over the exercise price per share of such Option multiplied by (ii) the number of shares of Co. Stock subject to such Option, payable no later than Co.'s next payroll date after the closing of the Merger. Further, as of the Effective Time, each award of restricted stock units of Co. that is outstanding immediately prior to the Effective Time and is subject to a performance-based vesting condition (a "Performance RSU") that relates solely to the value of Co. Stock will vest as to a number of shares determined under the terms of the award and will be cancelled and extinguished and converted into the right to receive the Cash Election Consideration, the Stock Election Consideration or the Mixed Election Consideration in accordance with the election made by the holder of such Performance RSU. At the Effective Time, each other award of restricted stock units of Co. that is outstanding and unvested will be assumed by Parent and continue to be subject to substantially the same terms and conditions (including vesting requirements) as in effect immediately prior to the Effective Time, except that the number of shares of Parent Common Stock subject to such assumed restricted stock unit awards will be equal to the product of (i) the number of shares of Co. Stock underlying such unvested restricted stock unit award as of immediately prior to the Effective Time multiplied by (ii) the sum of the (A) Exchange Ratio plus (B) the quotient obtained by dividing \$15.60 by the Equity Award Measurement Price. The "Equity Award Measurement Price" means the volume weighted average price per share of Parent Common Stock on NASDAQ for the ten (10) consecutive trading days ending on (and including) the third trading day immediately prior to the Effective Time. The transaction is expected to close in the middle of calendar year 2019, subject to approval by each company's shareholders, antitrust regulatory approvals and other customary closing conditions. The transaction values Co. at \$26.00 per share, or approximately \$3,200,000,000 in equity value and represents a premium of 37.7% to Co.'s closing price on Nov. 8, 2018.

FIREEYE INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	613,417	573,847
Cost & expenses	759,118	754,771
Operating income	(145,701)	(180,924)
Other income (expense), net	(14,390)	112
Net before taxes	(190,582)	(211,385)
Income taxes	4,144	3,385
Net income	(194,726)	(214,770)
Balance for common	(194,726)	(214,770)
Earnings common share		
Primary	\$(1.03)	\$(1.22)
Fully Diluted	\$(1.03)	\$(1.22)
Common Shares:		
Full Diluted	189,526	176,232
Year-end	193,601	

FOX FACTORY HOLDING CORP**Earnings, 9 mos. to (Consol. – \$000):**

	09/28/18	09/29/17
Total Revenues	462,415	354,540
Cost & expenses	386,170	301,467
Operating income	71,678	50,984
Interest expense	2,379	1,696
Other income (expense), net	(380)	(285)
Net before taxes	68,919	49,003
Income taxes	3,919	8,677
Net income	65,000	40,326
Earnings common share		
Primary	\$1.69	\$1.08
Fully Diluted	\$1.64	\$1.04
Common Shares:		
Full Diluted	38,913	38,700
Year-end	37,988	37,514

FREIGHTCAR AMERICA INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	228,684	330,233
Cost & expenses	249,535	348,575
Operating income	(20,851)	(18,342)
Other income (expense), net	1,421	219
Net before taxes	(19,515)	(18,222)
Income taxes	(4,603)	(6,798)
Net income	(14,912)	(11,424)
Earnings common share		
Primary	\$(1.20)	\$(0.92)
Fully Diluted	\$(1.20)	\$(0.92)
Common Shares:		
Full Diluted	12,316	12,283
Year-end	12,464	12,396

GAMING & LEISURE PROPERTIES, INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	752,410	730,610
Cost & expenses	199,740	189,897
Operating income	469,926	455,401
Other income (expense), net	(3,473)	
Net before taxes	297,779	293,745
Income taxes	4,194	6,406
Net income	293,585	287,339
Balance for common	293,174	286,869
Earnings common share		
Primary	\$1.37	\$1.37
Fully Diluted	\$1.37	\$1.35
Common Shares:		
Full Diluted	214,718	212,098
Year-end	214,038	212,603

GENTEX CORP.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Net Sales	1,380,654,978	1,335,302,109
Cost & expenses	998,028,730	945,937,823
Operating income	382,626,248	389,364,286
Other income (expense), net	578,655	(1,071,628)
Gains or losses	8,062,421	5,348,052
Net before taxes	391,267,324	393,640,710
Income taxes	59,658,782	117,317,687
Net income	331,608,542	276,323,023
Earnings common share		
Primary	\$1.23	\$0.97
Fully Diluted	\$1.22	\$0.96
Common Shares:		
Full Diluted	272,733,502	289,061,501
Year-end	262,116,951	283,902,844

GENTHERM INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	732,652	652,388
Operating income	51,955	76,110
Interest expense	3,661	3,633
Other income (expense), net	(9,938)	145
Net before taxes	39,077	50,702
Income taxes	9,807	10,233
Net income	29,270	40,469
Earnings common share		
Primary	\$0.80	\$1.10
Fully Diluted	\$0.80	\$1.10
Common Shares:		
Full Diluted	36,470	36,831
Year-end	35,749	36,678

GERON CORP.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	22,175	22,343
Operating income	(21,484)	(21,469)
Other income (expense), net	(404)	(59)
Net income	(19,717)	(20,487)
Earnings common share		
Primary	\$(0.11)	\$(0.13)
Fully Diluted	\$(0.11)	\$(0.13)
Common Shares:		
Full Diluted	173,188	159,187
Year-end	186,348	

GIBRALTAR INDUSTRIES INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	761,459	728,806
Cost & expenses	685,938	658,504
Operating income	75,521	70,302
Interest expense	9,305	10,612
Other income (expense), net	50	(811)
Net before taxes	66,266	58,879
Income taxes	15,574	21,090
Income contin. oper.		37,789
Income discont. oper.		(405)
Net income	50,692	37,384
Earnings common share		
Primary	\$1.59	\$1.18
Fully Diluted	\$1.56	\$1.16
Common Shares:		
Full Diluted	32,524	32,216
Year-end	32,064	32,275

GLYCOMIMETICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Cost & expenses	36,544,971	24,396,418
Operating income	(36,544,971)	(24,396,418)
Other income (expense), net	2,178,253	373,208
Net income	(34,366,718)	(24,023,210)
Earnings common share		
Primary	\$(0.85)	\$(0.86)
Fully Diluted	\$(0.85)	\$(0.86)
Common Shares:		
Full Diluted	40,345,071	27,814,781
Year-end	43,137,227	32,737,799

GOPRO INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	770,959	844,945
Cost & expenses	897,888	950,094
Operating income	(126,929)	(105,149)
Interest expense	13,804	9,152
Other income (expense), net	(268)	705
Net before taxes	(141,001)	(113,596)
Income taxes	(296)	13,429
Net income	(140,705)	(127,025)
Earnings common share		
Primary	\$(1.01)	\$(0.92)
Fully Diluted	\$(1.01)	\$(0.92)
Common Shares:		
Full Diluted	139,028	138,450
Year-end	129,873	136,752

GOVERNMENT PROPERTIES INCOME TRUST**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	170,164	95,756
Deprec., depl. & amort.	129,444	61,949
Operating income	23,296	51,657
Other income (expense), net	41,589	(804)
Equity earnings	1,112	(533)
Net before taxes	(4,154)	9,097
Income taxes	124	65
Net income	35,811	30,081
Balance for common	35,440	30,081
Earnings common share		
Primary	\$0.36	\$0.38
Fully Diluted	\$0.36	\$0.38
Common Shares:		
Full Diluted	99,075	79,852
Year-end	99,205	

GSI TECHNOLOGY INC**Earnings, 6 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	24,098	20,334
Cost & expenses	26,151	23,657
Operating income	(2,053)	(3,323)
Interest income	292	196
Other income (expense), net	(124)	5
Net before taxes	(1,885)	(3,122)
Income taxes	112	130
Net income	(1,997)	(3,252)
Earnings common share		
Primary	\$(0.09)	\$(0.16)

Fully Diluted	\$(0.09)	\$(0.16)
Common Shares:		
Full Diluted	21,707	20,922
Year-end	21,948	21,074

GULFPORT ENERGY CORP.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	939,094,000	922,455,000
Cost & expenses	348,561,000	292,227,000
Deprec., depl. & amort.	352,848,000	254,887,000
Operating income	237,685,000	375,341,000
Interest income	162,000	927,000
Other income (expense), net	159,565,000	(20,082,000)
Net before taxes	296,490,000	281,389,000
Income taxes	(69,000)	2,763,000
Net income	296,559,000	278,626,000
Earnings common share		
Primary	\$1.69	\$1.56
Fully Diluted	\$1.68	\$1.56
Common Shares:		
Full Diluted	176,440,461	179,130,570
Year-end	173,218,643	183,081,776

HALCON RESOURCES CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	166,265,000	352,688,000
Cost & expenses	117,452,000	493,650,000
Operating income	(3,584,000)	745,550,000
Other income (expense), net	(66,603,000)	(57,926,000)
Net before taxes		623,816,000
Income taxes		(5,000,000)
Net income	(100,709,000)	628,816,000
Balance for common	(100,709,000)	580,809,000
Earnings common share		
Primary	\$(0.64)	\$4.56
Fully Diluted	\$(0.64)	\$4.52
Common Shares:		
Full Diluted	156,628,000	128,410,000
Year-end	160,676,356	149,665,527

HARVARD BIOSCIENCE INC.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	86,916	55,761
Cost & expenses	83,691	55,612
Operating income	(758)	(1,009)
Other income (expense), net	(3,399)	(117)
Foreign currency	(28)	(488)
Net before taxes	(8,020)	(2,146)
Income taxes	(416)	(141)
Income contin. oper.	(7,604)	(2,005)
Net income	(5,784)	(1,864)
Earnings common share		
Primary	\$(0.16)	\$(0.05)
Fully Diluted	\$(0.16)	\$(0.05)
Common Shares:		
Full Diluted	36,170	34,706
Year-end	37,287	

HAWKINS INC**Earnings, 6 mos. to (Consol. – \$):**

	09/30/18	10/01/17
Net Sales	295,124,000	259,126,000
Cost & expenses	270,815,000	239,606,000
Operating income	24,309,000	19,520,000
Net before taxes	22,640,000	17,954,000
Income taxes	6,108,000	6,913,000
Net income	16,532,000	11,041,000
Earnings common share		
Primary	\$1.55	\$1.04
Fully Diluted	\$1.54	\$1.04
Common Shares:		
Full Diluted	10,714,381	10,641,731
Year-end	10,679,469	10,608,563

HEALTH INSURANCE INNOVATIONS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	213,487	180,986
Cost & expenses	190,307	152,307
Operating income	19,525	25,721
Other income (expense), net	(809)	(27)

Net before taxes	18,755	25,696
Income taxes	4,757	4,220
Net income	13,998	21,476
Earnings common share		
Primary	\$0.83	\$1.31
Fully Diluted	\$0.76	\$1.21
Common Shares:		
Full Diluted	13,303	11,693
Year-end	16,057	

HORIZON TECHNOLOGY FINANCE CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	12,383	9,697
Net income	9,902	9,917
Earnings common share		
Primary	\$0.86	\$0.86
Common Shares:		
Year-end	11,531	11,517

HUDSON GLOBAL INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	50,357	44,371
Cost & expenses	55,012	44,897
Deprec., depl. & amort.	3	238
Operating income	(4,658)	(764)
Other income (expense), net	(184)	(71)
Net before taxes	(4,680)	(842)
Income taxes	393	850
Income contin. oper.	(5,073)	(1,692)
Net income	8,487	(936)
Earnings common share		
Primary	\$0.26	\$(0.03)
Fully Diluted	\$0.26	\$(0.03)
Common Shares:		
Full Diluted	32,746	32,120
Year-end	32,048	

HURON CONSULTING GROUP INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	649,319,000	602,505,000
Cost & expenses	588,017,000	754,284,000
Operating income	35,021,000	180,328,000
Other income (expense), net	(5,131,000)	3,204,000
Net before taxes	15,254,000	190,935,000
Income taxes	4,365,000	(49,740,000)
Income contin. oper.	10,889,000	141,195,000
Net income	10,585,000	140,505,000
Earnings common share		
Primary	\$0.49	\$(6.56)
Fully Diluted	\$0.48	\$(6.56)
Common Shares:		
Full Diluted	21,947,000	21,413,000
Year-end	22,554,917	22,131,497

ICF INTERNATIONAL INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	960,063	907,988
Cost & expenses	877,480	824,095
Operating income	62,829	62,237
Interest expense	6,073	6,663
Other income (expense), net	(565)	24
Net before taxes	56,191	55,598
Income taxes	13,486	19,792
Net income	42,705	35,806
Earnings common share		
Primary	\$2.27	\$1.90
Fully Diluted	\$2.22	\$1.86
Common Shares:		
Full Diluted	19,256	19,218
Year-end	18,868	18,639

II-VI INC

Merger Development On Nov. 8, 2018, Finisar Corp. ("Finisar"), Co. and Mutation Merger Sub Inc. ("Mutation Merger Sub"), a wholly-owned subsidiary of Co., entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other things, Mutation Merger Sub will be merged with and into Finisar (the "Merger"), with Finisar surviving the Merger as a wholly-owned subsidiary of Co. At the time the Merger becomes effective (the "Effective Time"), each issued and outstanding share of common stock, par value \$0.001 per share, of Finisar

("Finisar Stock") (other than shares of Finisar Stock owned by Co. or Merger Subsidiary or any direct or indirect wholly owned subsidiary of Co., which will be cancelled without consideration, and holders of Finisar Stock, if any, who properly exercise their appraisal rights under the General Corporation Law of the State of Delaware) outstanding immediately prior to the Merger will be automatically cancelled and converted into the right to receive, for each share of Finisar Stock, at the stockholder's election and subject to proration in the event the cash consideration or Co. Common Stock (as defined below) consideration is oversubscribed, either (i) \$26.00 in cash (the "Cash Election Consideration"), (ii) 0.5546 of a share of common stock, no par value, of Co. ("Co. Common Stock") (the "Stock Election Consideration"), or (iii) a combination of (A) 0.2218 of a share of Co. Common Stock (the "Exchange Ratio") and (B) \$15.60 in cash, without interest (the "Mixed Election Consideration"). On an average basis across all shares of Finisar Stock (including the Options (as defined below) and Performance RSUs (as defined below)), at the closing of the Merger, 60% of the aggregate amount of the outstanding shares of Finisar Stock (including the Options and Performance RSUs) will be converted into the right to receive the Cash Election Consideration, with the remaining 40% converted into the right to receive the Stock Election Consideration. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase Finisar Stock (whether vested or unvested) (an "Option") shall automatically be cancelled and terminated and converted into the right to receive an amount of Mixed Election Consideration equal to the product of (i) the excess, if any, of the Cash Election Consideration over the exercise price per share of such Option multiplied by (ii) the number of shares of Finisar Stock subject to such Option, payable no later than Finisar's next payroll date after the closing of the Merger. Further, as of the Effective Time, each award of restricted stock units of Finisar that is outstanding immediately prior to the Effective Time and is subject to a performance-based vesting condition (a "Performance RSU") that relates solely to the value of Finisar Stock will vest as to a number of shares determined under the terms of the award and will be cancelled and extinguished and converted into the right to receive the Cash Election Consideration, the Stock Election Consideration or the Mixed Election Consideration in accordance with the election made by the holder of such Performance RSU. At the Effective Time, each other award of restricted stock units of Finisar that is outstanding and unvested will be assumed by Co. and continue to be subject to substantially the same terms and conditions (including vesting requirements) as in effect immediately prior to the Effective Time, except that the number of shares of Co. Common Stock subject to such assumed restricted stock unit awards will be equal to the product of (i) the number of shares of Finisar Stock underlying such unvested restricted stock unit award as of immediately prior to the Effective Time multiplied by (ii) the sum of the (A) Exchange Ratio plus (B) the quotient obtained by dividing \$15.60 by the Equity Award Measurement Price. The "Equity Award Measurement Price" means the volume weighted average price per share of Co. Common Stock on NASDAQ for the ten (10) consecutive trading days ending on (and including) the third trading day immediately prior to the Effective Time. The transaction is expected to close in the middle of calendar year 2019, subject to approval by each company's shareholders, antitrust regulatory approvals and other customary closing conditions. The transaction values Finisar at \$26.00 per share, or approximately \$3,200,000,000 in equity value and represents a premium of 37.7% to Finisar's closing price on Nov. 8, 2018.

IMMUNOGEN, INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	40,030,000	75,999,000
Cost & expenses	161,056,000	125,145,000
Operating income	(121,026,000)	(49,146,000)
Other income (expense), net	(590,000)	(20,826,000)
Gains or losses	2,845,000	551,000
Net income	(127,044,000)	(82,894,000)
Earnings common share		
Primary	\$(0.92)	\$(0.93)
Fully Diluted	\$(0.92)	\$(0.93)
Common Shares:		
Full Diluted	137,472,000	89,133,000
Year-end	149,049,000	115,563,000

INNOVIVA INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	609,099	528,923
Cost & expenses	563,796	475,159
Operating income	45,303	53,764
Other income (expense), net	42	42

Foreign currency	(409)	35
Net before taxes	35,406	49,406
Income taxes	4,155	15,678
Net income	31,251	33,728
Balance for common	31,139	33,540
Earnings common share		
Primary	\$1.60	\$1.73
Fully Diluted	\$1.57	\$1.70
Common Shares:		
Full Diluted	19,791	19,696
Year-end	19,613	19,529

INNOVIVA INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	181,146	147,697
Cost & expenses	20,115	30,502
Operating income	161,031	117,195
Other income (expense), net	(5,686)	(7,108)
Net income	137,113	75,758
Earnings common share		
Primary	\$1.30	\$0.71
Fully Diluted	\$1.19	\$0.67
Common Shares:		
Full Diluted	113,444	120,120
Year-end	101,039	108,002

INSULET CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	398,916	333,244
Cost & expenses	387,726	339,863
Operating income	11,190	(6,619)
Other income (expense), net	5,202	1,478
Net before taxes	(5,662)	(19,653)
Income taxes	939	318
Net income	(6,601)	(19,971)
Earnings common share		
Primary	\$(0.11)	\$(0.34)
Fully Diluted	\$(0.11)	\$(0.34)
Common Shares:		
Full Diluted	58,780	57,925
Year-end	59,069	58,156

INTEGRA LIFESCIENCES HOLDINGS CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	1,089,126,000	819,634,000
Cost & expenses	996,292,000	767,072,000
Operating income	76,890,000	37,586,000
Interest expense	325,000	160,000
Interest expense	50,750,000	18,073,000
Other income (expense), net	6,422,000	(3,691,000)
Net before taxes	32,887,000	15,982,000
Income taxes	(2,776,000)	(4,406,000)
Net income	35,663,000	20,388,000
Earnings common share		
Primary	\$0.43	\$0.27
Fully Diluted	\$0.43	\$0.26
Common Shares:		
Full Diluted	83,142,000	78,973,000
Year-end	85,133,000	78,385,000

INTELGENX TECHNOLOGIES CORP

Private Placement On Nov. 13, 2018, Co. announced that it closed a Private Placement through the issuance of 1,428,571 common shares ("Common Shares") at a subscription price of US\$0.70 per Common Share for gross proceeds of US\$1,000,000.

INTELGENX TECHNOLOGIES CORP

Stock Interest Change Development On Nov. 13, 2018, Tilray, Inc. ("Tilray") acquired 1,428,571 common shares of Co., through a private placement, at US\$0.70 per common share. The Common Shares issued to Tilray were subject to a four-month statutory hold period which expires Mar. 14, 2019. Additionally, under the Private Placement purchase agreement, Tilray agreed that until May 14, 2019 it would not cause or permit any transfer of any Common Shares.

INTERCEPT PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	126,524,000	93,269,000
Cost & expenses	330,043,000	323,912,000
Operating income	(203,519,000)	(230,643,000)
Other income (expense), net	5,051,000	3,388,000

Net income	(221,237,000)	249,095,000
Earnings common share		
Primary	\$(7.89)	\$(9.96)
Fully Diluted	\$(7.89)	\$(9.96)
Common Shares:		
Full Diluted	28,057,000	25,021,000
Year-end	29,654,468	25,102,079

INTREXON CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	117,389	153,953
Cost & expenses	286,117	265,351
Operating income	(168,728)	(111,398)
Other income (expense), net	(36,874)	2,420
Net before taxes	(192,519)	(95,039)
Income taxes	(19,535)	(2,164)
Net income	(172,984)	(92,875)
Earnings common share		
Primary	\$(1.31)	\$(0.75)
Fully Diluted	\$(1.31)	\$(0.75)
Common Shares:		
Full Diluted	128,844	119,741
Year-end	137,145	120,624

IRHYTHM TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	104,138	70,327
Cost & expenses	136,207	86,976
Operating income	(32,069)	(16,649)
Interest expense	2,580	2,522
Other income (expense), net	1,082	900
Net income	(33,567)	(18,271)
Earnings common share		
Primary	\$(1.41)	\$(0.81)
Fully Diluted	\$(1.41)	\$(0.81)
Common Shares:		
Full Diluted	23,764	22,446
Year-end	24,149	

IROBOT CORP**Earnings, 9 mos. to** (Consol. – \$000):

	09/29/18	09/30/17
Total Revenues	707,919	557,014
Cost & expenses	631,079	507,223
Operating income	76,035	49,618
Other income (expense), net	2,363	4,290
Net before taxes	78,398	53,908
Income taxes	15,597	7,565
Net income	62,801	46,343
Earnings common share		
Primary	\$2.27	\$1.68
Fully Diluted	\$2.19	\$1.61
Common Shares:		
Full Diluted	28,629	28,719
Year-end	27,671	27,874

JACK HENRY & ASSOCIATES, INC.**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	392,543	361,284
Cost & expenses	289,321	264,227
Operating income	103,222	97,057
Interest expense	147	189
Net before taxes	103,366	97,015
Income taxes	19,815	30,145
Net income	83,551	66,870
Earnings common share		
Primary	\$1.08	\$0.87
Fully Diluted	\$1.08	\$0.86
Common Shares:		
Full Diluted	77,537	77,646
Year-end	77,291	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	114,872	
Current assets	457,839	
Net property & equip.	286,497	
Total assets	2,033,102	
Liabilities:		
Current liabilities	420,226	
Stockholders' equity	1,368,564	
Net current assets	37,613	

KINSALE CAPITAL GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	165,210	136,034
Cost & expenses	129,839	108,738
Operating income	35,371	27,296
Net before taxes	35,371	27,296
Income taxes	6,032	8,319
Net income	29,339	18,977
Earnings common share		
Primary	\$1.39	\$0.90
Fully Diluted	\$1.35	\$0.88
Common Shares:		
Full Diluted	21,671	21,461
Year-end	21,227	21,029

LANCASTER COLONY CORP.**Earnings, 3 mos. to Sep 30**(Consol. – \$):

	2018	2017
Net Sales	316,654,000	298,916,000
Cost & expenses	267,534,000	254,740,000
Operating income	49,120,000	44,176,000
Other income (expense), net	1,314,000	508,000
Net before taxes	50,434,000	44,684,000
Income taxes	11,406,000	15,298,000
Net income	39,028,000	29,386,000
Balance for common	38,946,000	29,339,000
Earnings common share		
Primary	\$1.42	\$1.07
Fully Diluted	\$1.42	\$1.07
Common Shares:		
Full Diluted	27,514,000	27,451,000
Year-end	27,489,554	27,442,147

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	217,935,000	
Inventories	102,822,000	
Current assets	410,470,000	
Net property & equip.	195,772,000	
Total assets	840,183,000	
Liabilities:		
Current liabilities	107,501,000	
Stockholders' equity	674,019,000	
Net current assets	302,969,000	

LEXICON PHARMACEUTICALS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	45,816,000	57,288,000
Cost & expenses	137,254,000	163,184,000
Operating income	(91,438,000)	105,896,000
Interest expense	15,553,000	4,821,000
Net before taxes	(109,324,000)	(8,652,000)
Income taxes	(104,293,000)	100,672,000
Net income		
Earnings common share		
Primary	\$(0.99)	\$(0.96)
Fully Diluted	\$(0.99)	\$(0.96)
Common Shares:		
Full Diluted	105,800,000	105,119,000
Year-end	105,898,000	105,588,000

LHC GROUP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	1,223,758	709,438
Operating income	76,363	62,024
Interest expense	7,916	2,615
Net before taxes	68,447	59,409
Income taxes	14,832	20,410
Net income	53,615	38,999
Balance for common	43,022	31,678
Earnings common share		
Primary	\$1.63	\$1.79
Fully Diluted	\$1.61	\$1.77
Common Shares:		
Full Diluted	26,641	17,932
Year-end	30,674	17,745

LIBERTY BROADBAND CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	18,680	9,643
Cost & expenses	23,292	26,281

Operating income	(6,921)	(19,482)
Other income (expense), net	130,694	30,146
Gains or losses	(35,165)	(42,515)
Net before taxes	72,154	(45,531)
Income taxes	17,005	(18,245)
Net income	55,149	(27,286)
Earnings common share		
Primary	\$0.30	\$(0.15)
Fully Diluted	\$0.30	\$(0.15)
Common Shares:		
Full Diluted	182,586	183,164
Year-end	181,353	181,846

LIBERTY EXPEDIA HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	8,845,000	7,905,000
Cost & expenses	8,002,000	6,795,000
Deprec., depl. & amort.	1,442,000	1,669,000
Operating income	(599,000)	(559,000)
Other income (expense), net	(38,000)	(71,000)
Net before taxes	(740,000)	(718,000)
Income taxes	(231,000)	(259,000)
Net income	(509,000)	(459,000)
Earnings common share		
Primary	\$(1.98)	\$(1.70)
Fully Diluted	\$(1.98)	\$(1.70)
Common Shares:		
Full Diluted	58,000	58,000
Year-end	57,314	

MAMMOTH ENERGY SERVICES INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	1,411,886,000	322,533,000
Cost & expenses	976,577,000	272,830,000
Operating income	345,591,000	(14,651,000)
Other income (expense), net	(914,000)	(707,000)
Gains or losses		4,012,000
Net before taxes	342,023,000	(14,275,000)
Income taxes	174,265,000	(7,323,000)
Net income	167,758,000	(6,952,000)
Earnings common share		
Primary	\$3.75	\$(0.17)
Fully Diluted	\$3.73	\$(0.17)
Common Shares:		
Full Diluted	45,012,000	40,526,000
Year-end	44,755,678	44,502,223

MANTECH INTERNATIONAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	1,461,485	1,254,733
Cost & expenses	1,377,336	1,182,268
Operating income	84,149	72,465
Other income (expense), net	63	235
Equity earnings	(27)	(77)
Net before taxes	82,290	71,924
Income taxes	20,412	26,230
Net income	61,905	45,771
Earnings common share		
Primary	\$1.57	\$1.18
Fully Diluted	\$1.55	\$1.17
Common Shares:		
Full Diluted	26,633	25,845
Year-end	39,730	38,968

MARIN SOFTWARE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	42,806	57,299
Cost & expenses	82,072	80,098
Operating income	(39,266)	(22,799)
Other income (expense), net	1,008	(445)
Net before taxes	(38,258)	(23,244)
Income taxes	624	976
Net income	(38,882)	(24,220)
Earnings common share		
Primary	\$(6.75)	\$(4.31)
Fully Diluted	\$(6.75)	\$(4.31)
Common Shares:		
Full Diluted	5,763	5,625
Year-end	5,790	5,653

MARINUS PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Cost & expenses	26,906,000	14,106,000
Operating income	(26,906,000)	(14,106,000)
Interest income	292,000	116,000
Interest expense		159,000
Other income (expense), net		(11,000)
Net income	(26,614,000)	(14,160,000)
Earnings common share		
Primary	\$(0.66)	\$(0.60)
Fully Diluted	\$(0.66)	\$(0.60)
Common Shares:		
Full Diluted	40,392,084	23,531,745
Year-end	40,525,013	40,430,196

MASIMO CORP.**Earnings, 9 mos. to (Consol. – \$000):**

	09/29/18	09/30/17
Total Revenues	635,157	582,309
Cost & expenses	481,019	443,248
Operating income	154,138	139,061
Other income (expense), net	4,080	1,319
Net before taxes	158,218	140,380
Income taxes	11,609	7,856
Net income	146,609	132,524
Earnings common share		
Primary	\$2.78	\$2.57
Fully Diluted	\$2.59	\$2.37
Common Shares:		
Full Diluted	56,555	55,967
Year-end	52,996	51,671

MAXIM INTEGRATED PRODUCTS, INC.**Earnings, 3 mos. to (Consol. – \$000):**

	09/29/18	09/23/17
Total Revenues	638,495	575,676
Cost & expenses	403,539	388,758
Operating income	234,183	185,166
Net before taxes	233,637	180,952
Income taxes	36,214	26,419
Net income	197,423	154,533
Earnings common share		
Primary	\$0.71	\$0.55
Fully Diluted	\$0.70	\$0.54
Common Shares:		
Full Diluted	282,454	286,437
Year-end	277,063	281,487

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	1,598,772
Inventories	275,374
Current assets	3,311,525
Net property & equip.	573,014
Total assets	4,548,552
Liabilities:	
Current liabilities	928,277
Long-term debt	991,506
Stockholders' equity	1,912,323
Net current assets	2,383,248

MCGRATH RENTCORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	365,215,000	339,807,000
Cost & expenses	282,900,000	271,853,000
Operating income	82,315,000	67,954,000
Foreign currency	(505,000)	273,000
Net before taxes	72,677,000	59,503,000
Income taxes	17,520,000	23,307,000
Net income	55,157,000	36,196,000
Earnings common share		
Primary	\$2.29	\$1.51
Fully Diluted	\$2.25	\$1.50
Common Shares:		
Full Diluted	24,550,000	24,201,000
Year-end	24,176,000	24,032,000

MGP INGREDIENTS INC (NEW)**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	271,239	259,255
Cost & expenses	237,703	226,878
Operating income	33,536	32,377
Other income (expense), net		11,033
Net before taxes	32,706	42,476

Income taxes	7,244	13,292
Net income	25,462	29,184
Balance for common	24,971	28,378
Earnings common share		
Primary	\$1.48	\$1.70
Fully Diluted	\$1.48	\$1.70
Common Shares:		
Full Diluted	16,862	16,735
Year-end	16,852	16,724

MOBILEIRON INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	139,069	130,695
Cost & expenses	174,380	176,357
Operating income	(35,311)	(45,662)
Other income (expense), net	479	701
Net before taxes	(34,832)	(44,961)
Income taxes	1,043	881
Net income	(35,875)	(45,842)
Earnings common share		
Primary	\$(0.35)	\$(0.49)
Fully Diluted	\$(0.35)	\$(0.49)
Common Shares:		
Full Diluted	101,369	92,825
Year-end	105,420	

MONOLITHIC POWER SYSTEMS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	428,885,000	341,499,000
Cost & expenses	348,474,000	289,128,000
Operating income	80,411,000	52,371,000
Interest income	4,606,000	3,938,000
Other income (expense), net	(1,083,000)	(1,494,000)
Gains or losses	949,000	1,902,000
Foreign currency	915,000	(473,000)
Net before taxes	85,798,000	56,244,000
Income taxes	8,168,000	3,112,000
Net income	77,630,000	53,132,000
Earnings common share		
Primary	\$1.84	\$1.29
Fully Diluted	\$1.75	\$1.22
Common Shares:		
Full Diluted	44,450,000	43,384,000
Year-end	42,408,000	41,508,000

MONOTYPE IMAGING HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	175,339	170,773
Cost & expenses	163,260	159,509
Operating income	9,239	8,213
Interest income	403	309
Interest expense	2,756	2,365
Other income (expense), net	6	(24)
Gains or losses	138	(290)
Foreign currency	30	(4,544)
Net before taxes	7,060	1,299
Income taxes	4,243	1,609
Net income	2,817	(310)
Balance for common	2,226	(310)
Earnings common share		
Primary	\$0.06	\$(0.01)
Fully Diluted	\$0.06	\$(0.01)
Common Shares:		
Full Diluted	40,455	39,576
Year-end	41,859	41,782

NATHAN'S FAMOUS, INC.**Earnings, 6 mos. to (Consol. – \$000):**

	09/23/18	09/24/17
Total Revenues	59,498	62,274
Cost & expenses	41,247	44,355
Operating income	17,567	17,184
Interest income	176	70
Interest expense	5,301	7,326
Other income (expense), net	540	42
Net before taxes	12,982	9,970
Income taxes	3,703	3,928
Net income	9,279	6,042
Earnings common share		
Primary	\$2.22	\$1.45
Fully Diluted	\$2.19	\$1.43

Common Shares:		
Full Diluted	4,229	4,213
Year-end	4,192	4,185

NETGEAR INC**Earnings, 9 mos. to (Consol. – \$000):**

	09/30/18	10/01/17
Total Revenues	1,112,379	1,009,863
Cost & expenses	1,097,276	942,587
Operating income	15,103	67,276
Interest income	3,310	1,388
Other income (expense), net	638	1,384
Net before taxes	19,051	70,048
Income taxes	9,541	18,678
Net income	9,510	51,370
Earnings common share		
Primary	\$0.33	\$1.59
Fully Diluted	\$0.31	\$1.54
Common Shares:		
Full Diluted	32,826	33,269
Year-end	31,746	31,731

NEWLINK GENETICS CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	12,272	18,613
Cost & expenses	63,764	77,443
Operating income	(51,492)	(58,830)
Interest income	1,510	353
Interest expense	51	116
Other income (expense), net	16	(101)
Net before taxes	(50,017)	(58,694)
Income taxes	(6,991)	(429)
Net income	(43,026)	(58,265)
Earnings common share		
Primary	\$(1.16)	\$(1.98)
Fully Diluted	\$(1.16)	\$(1.98)
Common Shares:		
Full Diluted	37,179	29,462
Year-end	37,217	31,320

NIC INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	266,251,000	253,036,000
Cost & expenses	197,110,000	187,011,000
Operating income	62,490,000	60,914,000
Interest income	212,000	
Net before taxes	62,702,000	60,914,000
Income taxes	14,280,000	20,140,000
Net income	48,422,000	40,774,000
Balance for common	47,897,000	40,393,000
Earnings common share		
Primary	\$0.72	\$0.61
Fully Diluted	\$0.72	\$0.61
Common Shares:		
Full Diluted	66,507,000	66,188,000
Year-end	66,567,000	66,268,000

NUANCE COMMUNICATIONS INC

Interest Sale Development On Nov. 12, 2018, Co. announced a definitive agreement to sell its Document Imaging division to Kofax, Inc. for \$400,000,000 in cash. The deal is expected to close in Q1 2019.

NUTRISYSTEM INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	561,496	565,720
Cost & expenses	493,806	487,889
Deprec., depl. & amort.	11,531	11,321
Operating income	56,159	66,510
Net before taxes	56,671	66,584
Income taxes	11,738	19,638
Net income	44,933	46,946
Balance for common	44,572	46,542
Earnings common share		
Primary	\$1.51	\$1.57
Fully Diluted	\$1.50	\$1.54
Common Shares:		
Full Diluted	29,797	30,164
Year-end	29,419	30,040

OBALON THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	35,370	30,691
Operating income	(28,305)	(24,469)
Interest expense	164	110
Other income (expense), net	(155)	(66)
Net income	(28,624)	(24,645)
Earnings common share		
Primary	\$(1.60)	\$(1.48)
Fully Diluted	\$(1.60)	\$(1.48)
Common Shares:		
Full Diluted	17,837	16,649
Year-end	23,280	17,372

ORTHOPEDIATRICS CORP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	42,991	33,939
Cost & expenses	50,678	36,207
Operating income	(7,687)	(2,268)
Interest expense	1,722	1,857
Other income (expense), net	(148)	38
Net income	(9,557)	(4,087)
Balance for common	(9,557)	(8,451)
Earnings common share		
Primary	\$(0.77)	\$(4.82)
Fully Diluted	\$(0.77)	\$(4.82)
Common Shares:		
Full Diluted	12,418	1,755
Year-end	12,808	2,488

PACIRA PHARMACEUTICALS INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	242,163	207,552
Cost & expenses	238,510	240,953
Operating income	3,653	(33,401)
Interest income	4,493	2,805
Interest expense	16,195	12,942
Other income (expense), net	(699)	(3,563)
Net before taxes	(8,748)	(47,101)
Income taxes	8	105
Net income	(8,756)	(47,206)
Earnings common share		
Primary	\$(0.21)	\$(1.19)
Fully Diluted	\$(0.21)	\$(1.19)
Common Shares:		
Full Diluted	40,833	39,540
Year-end	41,061	40,565

PERFICIENT INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	366,672,000	351,783,000
Cost & expenses	327,043,000	313,057,000
Operating income	24,543,000	24,041,000
Other income (expense), net	(43,000)	84,000
Net before taxes	22,782,000	22,681,000
Income taxes	5,699,000	10,535,000
Net income	17,083,000	12,146,000
Earnings common share		
Primary	\$0.52	\$0.37
Fully Diluted	\$0.50	\$0.36
Common Shares:		
Full Diluted	33,846,000	34,085,000
Year-end	31,920,534	33,445,194

PROOFPOINT INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	518,515	372,762
Cost & expenses	599,187	415,944
Operating income	(80,672)	(43,182)
Other income (expense), net	(715)	884
Net before taxes	(96,492)	(59,845)
Income taxes	(13,978)	3,410
Net income	(82,514)	(63,255)
Earnings common share		
Primary	\$(1.61)	\$(1.44)
Fully Diluted	\$(1.61)	\$(1.44)
Common Shares:		
Full Diluted	51,214	43,850
Year-end	54,483	

RBC BEARINGS INC

Earnings, 6 mos. to (Consol. – \$000):

	09/29/18	09/30/17
Net Sales	348,901	328,214
Cost & expenses	277,019	270,818
Operating income	71,882	57,396
Interest expense	3,157	3,943
Other income (expense), net	(1,370)	(754)
Net before taxes	67,355	52,699
Income taxes	9,777	16,067
Net income	57,578	36,632
Earnings common share		
Primary	\$2.38	\$1.53
Fully Diluted	\$2.34	\$1.51
Common Shares:		
Full Diluted	24,635	24,251
Year-end	24,448	24,949

REPLIGEN CORP.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	142,090,000	99,624,000
Cost & expenses	123,955,000	88,881,000
Operating income	18,135,000	10,743,000
Interest expense	5,008,000	4,804,000
Other income (expense), net	187,000	(548,000)
Gains or losses	1,251,000	308,000
Net before taxes	14,565,000	5,699,000
Income taxes	3,586,000	(10,476,000)
Net income	10,979,000	16,175,000
Earnings common share		
Primary	\$0.25	\$0.44
Fully Diluted	\$0.24	\$0.43
Common Shares:		
Full Diluted	45,132,115	37,386,333
Year-end	43,853,389	43,559,081

ROYAL GOLD INC

Earnings, 3 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	99,992,000	112,476,000
Cost & expenses	32,108,000	31,064,000
Operating income	25,333,000	41,720,000
Other income (expense), net	(1,468,000)	
Net before taxes	16,091,000	34,092,000
Income taxes	4,115,000	7,544,000
Net income	11,976,000	26,548,000
Earnings common share		
Primary	\$0.23	\$0.44
Fully Diluted	\$0.23	\$0.44
Common Shares:		
Full Diluted	65,497,159	65,404,680
Year-end	65,394,898	65,306,271

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	117,078,000	
Inventories	10,011,000	
Current assets	159,430,000	
Total assets	2,672,866,000	
Liabilities:		
Current liabilities	37,371,000	
Long-term debt	354,939,000	
Stockholders' equity	2,103,221,000	
Net current assets	122,059,000	

RTI SURGICAL, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	209,639,000	208,747,000
Cost & expenses	212,082,000	176,101,000
Operating income	(2,443,000)	32,646,000
Interest income	31,000	
Interest expense	2,223,000	2,475,000
Other income (expense), net	(309,000)	
Foreign currency	(23,000)	5,000
Net before taxes	(4,967,000)	30,176,000
Income taxes	(1,646,000)	16,251,000
Net income	(3,321,000)	13,925,000
Balance for common	(5,441,000)	11,153,000
Earnings common share		
Primary	\$(0.09)	\$0.19
Fully Diluted	\$(0.09)	\$0.19
Common Shares:		
Full Diluted	63,517,958	59,954,964
Year-end	63,461,700	60,544,896

SANFILIPPO (JOHN B) & SON INC

Earnings, 3 mos. to (Consol. – \$000):

	09/27/18	09/28/17
Net Sales	204,288	215,664
Cost & expenses	194,236	198,049
Operating income	10,052	17,615
Interest expense	879	781
Other income (expense), net	(776)	(1,114)
Net before taxes	8,397	15,720
Income taxes	1,791	5,009
Net income	6,606	10,711
Earnings common share		
Primary	\$0.58	\$0.94
Fully Diluted	\$0.57	\$0.94
Common Shares:		
Full Diluted	11,492	11,442
Year-end	11,345	11,297

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	1,215	
Inventories	181,031	
Current assets	245,323	
Net property & equip.	110,632	
Total assets	415,427	
Liabilities:		
Current liabilities	140,002	
Long-term debt	25,537	
Stockholders' equity	221,347	
Net current assets	105,321	

SEI INVESTMENTS CO

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,219,110	1,118,333
Cost & expenses	822,149	769,673
Operating income	339,026	289,981
Interest expense	511	571
Other income (expense), net	123,406	109,213
Gains or losses	(460)	1,036
Net before taxes	470,607	404,587
Income taxes	80,773	122,342
Net income	389,834	282,245
Earnings common share		
Primary	\$2.48	\$1.78
Fully Diluted	\$2.41	\$1.74
Common Shares:		
Full Diluted	162,053	161,866
Year-end	155,475	157,405

SILVERCREST ASSET MANAGEMENT GROUP INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	73,840	66,887
Cost & expenses	57,927	51,670
Operating income	15,913	15,217
Other income (expense), net	(5)	24
Net before taxes	16,071	15,189
Income taxes	3,935	4,575
Net income	12,136	10,614
Earnings common share		
Primary	\$0.81	\$0.67
Fully Diluted	\$0.81	\$0.67
Common Shares:		
Full Diluted	8,271	8,109
Year-end	13,452	13,201

SKYWORKS SOLUTIONS, INC.

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	09/28/18	09/29/17	09/30/16
		(revised)	(revised)
Net revenue	3,868,000	3,651,400	3,289,000
Cost of goods sold	1,917,300	1,809,600	1,623,800
Gross profit	1,950,700	1,841,800	1,665,200
Research & development expenses	404,500	355,200	312,400
Selling, general & administrative expenses	207,800	204,600	195,900
Amortization of intangibles	18,300	27,600	33,400
Restructuring & other charges			

(credits).....	800	600	4,800
Total operating expenses.....	631,400	588,000	546,500
Operating income (loss).....	1,319,300	1,253,800	1,118,700
Other income (expense), net.....	12,800	3,200	(6,600)
Merger termination fee.....	(88,500)
Income (loss) before income taxes - United States.....	712,200	681,200	697,500
Income (loss) before income taxes - foreign.....	619,900	575,800	503,100
Income (loss) before income taxes.....	1,332,100	1,257,000	1,200,600
Current tax expense (benefit) - federal.....	347,700	215,700	181,800
Current tax expense (benefit) - state.....	300	300	100
Current tax expense (benefit) - foreign.....	31,200	24,400	25,800
Total current tax expense (benefit).....	379,200	240,400	207,700
Deferred tax expense (benefit) - federal.....	20,300	5,000	(800)
Deferred tax expense (benefit) - foreign.....	14,200	1,400	(1,500)
Total deferred tax expense (benefit).....	34,500	6,400	(2,300)
Provision (benefit) for income taxes.....	413,700	246,800	205,400
Net income (loss).....	918,400	1,010,200	995,200
Weighted average shares outstanding - basic.....	181,300	184,300	188,700
Weighted average shares outstanding - diluted.....	183,200	186,700	192,100
Year end shares outstanding.....	177,400	183,100	184,900
Net earnings (loss) per share - basic.....	\$5.06	\$5.48	\$5.27
Net earnings (loss) per share - diluted.....	\$5.01	\$5.41	\$5.18
Cash dividends declared & paid per share.....	\$1.34	\$1.16	\$1.06
Total number of employees.....	9,400	8,400	7,300
Number of common stockholders.....	12,404	14,389	19,882

□ As is; □ Approximately; □ As of November 7, 2018; □ As of November 3, 2017; □ As of November 14, 2016

Consolidated Balance Sheet, Years Ended (\$000):			
	09/28/18	09/29/17 (revised)	
Cash & cash equivalents.....	733,300	1,616,800	
Marketable securities.....	294,100	...	
Receivables, gross.....	656,400	455,200	
Allowance for doubtful accounts.....	600	500	
Receivables, net.....	655,800	454,700	
Raw materials.....	20,200	24,600	
Work-in-process.....	340,700	330,600	
Finished goods.....	124,800	123,000	
Finished goods held on consignment by customers.....	4,500	15,300	
Inventory.....	490,200	493,500	
Other current assets.....	88,800	68,700	
Total current assets.....	2,262,200	2,633,700	
Land & improvements.....	11,600	11,600	
Buildings & improvements.....	238,000	137,800	
Furniture & fixtures.....	31,500	29,500	
Machinery & equipment.....	2,089,600	1,715,300	
Construction in progress.....	179,000	164,800	
Property, plant & equipment, gross.....	2,549,700	2,059,000	
Accumulated depreciation.....	1,408,800	1,176,700	

Property, plant & equipment, net.....	1,140,900	882,300	
Goodwill.....	1,189,800	883,000	
Intangible assets, net.....	143,700	67,800	
Deferred tax assets, net.....	36,500	66,500	
Marketable securities.....	22,800	...	
Other assets.....	33,000	40,300	
Total assets.....	4,828,900	4,573,600	
Accounts payable.....	229,900	258,400	
Accrued compensation & benefits.....	85,200	68,100	
Other current liabilities.....	74,600	61,400	
Total current liabilities.....	389,700	387,900	
Long-term tax liabilities.....	310,500	92,900	
Other long-term liabilities.....	31,700	27,100	
Total liabilities.....	731,900	507,900	
Common stock.....	44,400	45,800	
Additional paid-in capital.....	3,061,000	2,893,800	
Treasury stock, at cost.....	2,732,500	1,925,000	
Retained earnings (accumulated deficit).....	3,732,900	3,059,600	
Accumulated other comprehensive income (loss).....	(8,800)	(8,500)	
Total stockholders' equity.....	4,097,000	4,065,700	

Recent Dividends:

1. Skyworks Solutions, Inc. common.

ExDate	Amt	Declared	Record	Payable
02/03/2015	0.13	01/21/2015	02/05/2015	03/03/2015
05/12/2015	0.13	04/30/2015	05/14/2015	06/04/2015
08/04/2015	0.26	06/18/2015	08/06/2015	08/27/2015
11/17/2015	0.26	11/05/2015	11/19/2015	12/10/2015
02/09/2016	0.26	01/28/2016	02/11/2016	03/03/2016
05/10/2016	0.26	04/28/2016	05/12/2016	06/02/2016
08/02/2016	0.28	07/21/2016	08/04/2016	08/25/2016
11/15/2016	0.28	11/03/2016	11/17/2016	12/08/2016
01/31/2017	0.28	01/19/2017	02/02/2017	02/23/2017
05/12/2017	0.28	04/27/2017	05/16/2017	06/06/2017
08/04/2017	0.32	07/20/2017	08/08/2017	08/29/2017
11/20/2017	0.32	11/06/2017	11/21/2017	12/12/2017
02/21/2018	0.32	02/06/2018	02/22/2018	03/15/2018
05/21/2018	0.32	05/03/2018	05/22/2018	06/12/2018
08/06/2018	0.38	07/19/2018	08/07/2018	08/28/2018

Annual Dividends:

1. Skyworks Solutions, Inc. common.

2015.....	0.78	2016.....	1.08	2017.....	1.20
2018.....	1.02				

SOLAREDEGE TECHNOLOGIES INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues.....	673,567	417,705
Cost & expenses.....	558,101	361,190
Operating income.....	115,466	56,515
Other income (expense), net.....	(2,585)	7,671
Net before taxes.....	112,881	64,186
Income taxes.....	(3,016)	(484)
Net income.....	115,897	64,670
Earnings common share		
Primary.....	\$2.57	\$1.55
Fully Diluted.....	\$2.41	\$1.44
Common Shares:		
Full Diluted.....	48,091	44,938
Year-end.....	45,750

SPARK ENERGY INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues.....	777,414	563,279
Net Sales.....	773,616	563,960
Cost & expenses.....	729,476	490,176
Operating income.....	8,141	42,668
Interest expense.....	7,323	8,760
Net before taxes.....	1,525	34,010
Income taxes.....	602	5,265
Net income.....	923	28,745
Balance for common.....	(5,298)	3,590

Earnings common share

Primary.....	\$(0.40)	\$0.27
Fully Diluted.....	\$(0.40)	\$0.27
Common Shares:		
Full Diluted.....	13,254	13,315
Year-end.....	34,879	34,631

SPRING PHARMACEUTICAL GROUP INC

History: Incorporated in Florida in Jan. 1989 as Southstar Productions, Inc. Name subsequently changed to Medical Technology & Innovations Inc. Reincorporated in Delaware on Apr. 4, 2007. Name changed to itLinkz Group, Inc., on Apr. 5, 2007. Name changed to China YCT International Group Inc. on Nov. 23, 2007. Present name adopted on Aug. 31, 2018.

In Oct. 1995, Co. acquired Medical Technology, Inc.

On Aug. 1, 1996, Co. acquired the net assets and the right to the name of Steridyne Corporation.

On Apr. 1, 1999, Co. acquired certain key operating assets of the thermometer business of Florida Medical Corporation.

On Sept. 6, 2002, Co. disposed of all of its assets and ceased operations pertaining to the medical products side of the business.

On June 22, 2005, Co. formed a subsidiary called World Nurse Space, Inc.

On Sept. 25, 2006, Co. formed a subsidiary called itLinkz Corporation.

On Sept. 28, 2007, Co. acquired the outstanding capital stock of Landway Nano Bio-Tech Group for a consideration of 500 shares of Series B Preferred Stock.

In Mar. 2010, Co. purchased a patent from Shandong Yong Chun Tang for \$6,740,000, which enables Co. to manufacture and distribute the Huoliyuan Capsule.

On Feb. 28, 2011, Co. acquired U.S. patent No. 6,475,531 B1 titled Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function (the Influenza Patent) through a purchase agreement with L.Y. Research Corp. and its subsidiary, and LY (HK) Biotech Limited., as amended as of Aug. 15, 2011 (the Acquisition Agreement.) In consideration for the purchase of the patent, Co. issued LY Holding Limited, an affiliate of LY Research Corp., 44,254,952 shares of common stock, which consideration may increase to a maximum of 75,865,631 shares of Co.'s common stock pursuant to the Acquisition Agreement. The total value of the consideration on the acquisition date is \$32,748,665 which is calculated by the total issuing shares, multiplying Co.'s quoted stock price \$0.74 per share on Feb. 28, 2011. On Oct. 21, 2011, Co. entered into an Amendment Agreement with L.Y. Research to amend the purchase agreement, dated as of Feb. 28, 2011, and amended and restated as of Aug. 15, 2011 (the Purchase Agreement) with respect to the acquisition of U.S. Patent #6,475,531B1 titled Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function (the LY Patent). The Amendment Agreement added the following terms:

in the event that Co. cannot, within one year from Oct. 21, 2011, either raise a minimum of \$20,000,000 in gross proceeds from a debt or equity financing, or a series of debt and/or equity financings, or list its common stock on NASDAQ or a foreign stock exchange, then the shares issued pursuant to the Purchase Agreement shall be returned to Co. and the LY Patent shall be returned to LY Research and the Purchase Agreement, as amended, shall be cancelled and of no further force or effect; and LY Research agrees that it waives its right to vote the shares and receive any dividends or other distributions from Co. until the earlier of (a) completion of the financing or (b) the listing of the shares of common stock of Co. on NASDAQ or a foreign stock exchange.

On Oct. 19, 2018, Paritz & Company, P.A. resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Prager Metis CPAs LLC as its new independent public accounting firm.

Business: Spring Pharmaceutical Group is a health care company, which is engaged in developing, manufacturing and selling Chinese medicines, including manufacturing its medicines made primarily from panax ginseng leaves extract, developing acer truncatum bunge planting bases, processing and selling acer truncatum bunge seed oils, and distributing health care products manufactured by another company in the People's Republic of China. The Huoliyuan capsule is used with respect to various medical conditions for the human cardiovascular system and as an aid in the treatment of chronic hepatitis, diabetes, insomnia, memory loss, menopause syndrome, and other maladies.

Property: Co. maintains its principal executive offices in Shandong Province, China.

Co.'s subsidiary, Shandong Spring Pharmaceutical Co., Ltd., operates on a property of approx. 56,894 sq. m. (approx.14.06 acres)

in Shandong Province. Besides housing Co.'s executive offices, the property includes a manufacturing facility measuring 17,200 sq. m. (approx.185,139.25 sq. ft.) and a research facility measuring 3,000 sq. m. (approx. 32,291.73 sq. ft.). As of Mar. 31, 2018, Co. leased a total of approx. 2,324.77 acres of farmland.

Subsidiaries

(wholly owned unless otherwise noted)

Landway Nano Bio-Tech Group, Inc.
Shandong Spring Pharmaceutical Co., Ltd. (China (Peoples Rep. Of)) (97%)

Officers

Tinghe Yan, Chairman; Chief Executive Officer; Subsidiary Officer
Li Chuanmin, Chief Financial Officer; Subsidiary Officer
Sun Maogang, Subsidiary Officer
Zhang Qiang, Subsidiary Officer
Ding Xuzhong, Subsidiary Officer
Shao Zecheng, Subsidiary Officer

Directors

Tinghe Yan, Chairman
Jirui Zhang, Director
Dong Li, Director
Robert J. Fanella, Director
Wengao Zhang, Director

Auditors: Prager Metis CPAs, LLC

Transfer agent and Registrar: Interwest Transfer Co., Inc, Holland, UT

Annual Meeting: In October

Shareholder Relations: Zecheng Shao, Vice President Tel: 86 537 4268271

No. of Stockholders: Aug. 29, 2018, 777, record

No. of Employees: June 15, 2018, 313

Address:11 Quanxing Road Sishui County, , Shandong Province 373200, China (Peoples Rep. Of)

Tel: 86 537 4268271

Web: www.yctgroup.com

Email: yct@yongchuntang.com

Consolidated Income Statement, Years Ended Mar. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Sales	64,942,737	56,463,164	47,827,108
Cost of goods sold	39,603,995	33,284,237	26,554,022
Gross profit	25,338,742	23,178,927	21,273,086
Selling expenses	4,984,794	3,934,334	3,759,920
General & administrative expenses	4,719,402	4,248,095	4,446,983
Research & development expenses	492,078	809,485	724,287
Impairment of assets	332,090	986,406	1,114,942
Total operating expenses	10,528,364	9,978,320	10,046,132
Income (loss) from operations	14,810,378	13,200,607	11,226,954
Gain on disposal of acer truncatum bunge plants	642,532
Interest income (expense)	124,410	54,672	30,850
Income (loss) before tax	15,577,320	13,255,279	11,257,804
Current income taxes	3,499,474	3,520,126	3,055,958
Deferred income taxes	339,358	(319,501)	(214,923)
Income tax provision	3,838,832	3,200,625	2,841,035
Net income (loss)	11,738,488	10,054,654	8,416,769
Less: Net loss attributable to non-controlling interest	(352,155)	23,649	...
Net income attributable to company	11,386,333	10,078,303	8,416,769
Weighted average outstanding shares			

- basic	29,789,168	29,763,531	29,709,706
Weighted average outstanding shares			
- diluted	29,789,168	29,763,531	29,709,706
Year end shares outstanding	29,789,168	29,789,168	29,720,690
Net income (loss) per share - basic	\$0.38	\$0.34	\$0.28
Net income (loss) per share - diluted	\$0.38	\$0.34	\$0.28
Number of full time employees	313	312	313
Number of common stockholders	777	770	768

Reclassified to conform with 2017 presentation; Including amount from a related party - cost of good sold: \$14,404,967; Including amount from a related party - cost of good sold: \$11,015,268; Including amount from a related party - cost of good sold: \$8,623,417; As of June 15, 2018; As of August 29, 2018

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2018	2017
		(revised)
Cash & cash equivalents	25,353,360	10,308,622
Accounts receivable	174,558	1,134,967
Raw materials	233,138	1,276,254
Packaging materials	652,179	476,803
Work-in-process	686,234	1,373,919
Finished goods	811,831	2,356,064
Inventories	2,383,382	5,483,040
Purchase deposit to related party	1,412,864	650,790
Prepaid leases - current portion	741,583	900,547
Total current assets	30,065,747	18,477,966
Prepaid leases	641,349	1,265,252
Development cost of acer truncatum bunge planting	48,984,881	42,055,972
Machinery & equipment	3,594,861	2,254,813
Office equipment & automobiles	769,589	717,259
Building	13,606,722	12,401,320
Leasehold improvements	4,240,568	2,803,052
Property, plant & equipment, gross	22,211,740	18,176,444
Less: accumulated depreciation & amortization	5,418,327	3,689,309
Plant, property & equipment, net	16,793,413	14,487,135
Intangible assets, net	11,862,017	12,042,758
Deferred tax assets	200,387	508,521
Security deposit to related party	1,590,305	1,449,422
Total assets	110,138,099	90,287,026
Accounts payable to related party	...	706,048
Accounts payable & other accrued expense	372,782	251,307
Advance from customer	445,829	...
Corporate income tax	519,875	1,382,382
Value-added tax	580,429	576,086
Other tax & fees	63,894	69,722
Taxes payable	1,164,198	2,028,190
Total current liabilities	1,982,809	2,985,545
Preferred stock	22,500	22,500
Common stock	29,789	29,789
Additional paid-in capital	4,322,838	4,322,838
Statutory reserve	1,828,504	1,828,504
Retained earnings (accumulated deficit)	94,447,937	83,061,604
Accumulated other comprehensive income	4,455,017	(4,386,845)
Total stockholders' equity attributable to the Company	105,106,585	84,878,390
Non-controlling interests	3,048,705	2,423,091
Total stockholders' equity	108,155,290	87,301,481

Reclassified to conform with 2018 presentation

Capital Stock: 1. Spring Pharmaceutical Group Inc 12% series A noncumulative preferred; par \$ 500..

AUTHORIZED-45 shs.

OUTSTANDING-Mar. 31, 2018, 45 shs; par \$ 500..

CONVERTIBLE-The preferred stock is convertible into 599 shares of Co.'s common stock.

CAPITAL HISTORY-On Apr. 4, 2007, the number of shares authorized preferred stock was changed to 45, \$500 par value.

2. Spring Pharmaceutical Group Inc common; par \$ 0.001.

AUTHORIZED-100,000,000 shs.

OUTSTANDING-Mar. 31, 2018, 29,789,168 shs; par \$ 0.001.

STOCK SPLITS-No par shares reverse split 1-for-25 Dec. 4, 2001

\$0.001 par shares reverse split 1-for-28 Nov. 26, 2007.

OWNERSHIP-As of June 29, 2018, officers and directors as a group beneficially owned 38.19% of Co.'s outstanding common stock.

OPTIONS-Mar. 31, 2016, outstanding, 2,600,000.

PRIMARY EXCHANGE-National Bulletin Board (NBB): CYIG.

OFFERED-(2,300,000 shares) at \$0.13 a share on Jan. 16, 2007.

PAR CHANGE-To \$0.00 in 2007. (From no par)

CAPITAL HISTORY-On Apr. 4, 2007, the number of shares of authorized common stock was increased from 28,000,000 shares, no par value, to 100,000,000 shares, \$0.001 par value.

SPROUTS FARMERS MARKET INC

Earnings, 9 mos. to (Consol. - \$000):

	09/30/18	10/01/17
Net Sales	3,937,998	3,520,679
Cost & expenses	3,743,831	3,331,693
Operating income	194,167	188,986
Interest expense	20,028	15,447
Other income (expense), net	325	388
Net before taxes	174,464	173,927
Income taxes	28,631	55,186
Net income	145,833	118,741
Earnings common share		
Primary	\$1.13	\$0.87
Fully Diluted	\$1.12	\$0.86
Common Shares:		
Full Diluted	130,537	138,860
Year-end	127,604	133,071

STAAR SURGICAL CO.

Earnings, 9 mos. to (Consol. - \$000):

	09/28/18	09/29/17
Net Sales	92,768	65,759
Cost & expenses	87,360	68,130
Operating income	5,408	(2,371)
Other income (expense), net	526	417
Foreign currency	(545)	738
Net before taxes	5,324	(1,304)
Income taxes	1,452	697
Net income	3,872	(2,001)
Earnings common share		
Primary	\$0.09	\$(0.05)
Fully Diluted	\$0.09	\$(0.05)
Common Shares:		
Full Diluted	44,618	40,939
Year-end	44,104	41,156

T-MOBILE US INC

Earnings, 9 mos. to Sep 30(Consol. - \$Millions):

	2018	2017
Total Revenues	31,865	29,845
Cost & expenses	22,847	21,570
Deprec., depl. & amort.	4,846	4,499
Operating income	4,172	3,776
Interest income	17	15
Other income (expense), net	(51)	(89)
Net before taxes	3,079	2,447
Income taxes	831	618
Net income	2,248	1,829
Balance for common	2,248	1,788
Earnings common share		
Primary	\$2.65	\$2.15
Fully Diluted	\$2.62	\$2.10
Common Shares:		
Full Diluted	858	872
Year-end	848	832

T2 BIOSYSTEMS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	8,708	3,005
Cost & expenses	40,204	42,491
Operating income	(31,496)	(39,486)
Other income (expense), net	402	260
Net income	(36,004)	(44,234)
Earnings common share		
Primary	\$(0.91)	\$(1.43)
Fully Diluted	\$(0.91)	\$(1.43)
Common Shares:		
Full Diluted	39,363	30,874
Year-end	44,039	35,797

TANDEM DIABETES CARE INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	107,667,000	67,306,000
Cost & expenses	152,859,000	120,667,000
Operating income	(45,192,000)	(53,361,000)
Other income (expense), net	(74,355,000)	
Net income	(126,299,000)	(61,627,000)
Earnings common share		
Primary	\$(2.81)	\$(13.79)
Fully Diluted	\$(2.81)	\$(13.79)
Common Shares:		
Full Diluted	44,993,000	4,468,000
Year-end	57,364,000	

TESLA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	14,235,395	8,470,502
Cost & expenses	15,037,004	9,504,447
Operating income	(801,609)	(1,033,945)
Other income (expense), net	36,071	(83,696)
Net before taxes	(1,236,701)	(1,429,131)
Income taxes	35,959	40,640
Net income	(1,272,660)	(1,469,771)
Earnings common share		
Primary	\$(6.56)	\$(7.80)
Fully Diluted	\$(6.56)	\$(7.80)
Common Shares:		
Full Diluted	170,019	164,897
Year-end	171,578	168,017

TILRAY INC

Acquisition Completed On Nov. 13, 2018, Co. acquired 1,428,571 common shares of IntelGenx Technologies Corp. ("IntelGenx"), through a private placement, at \$0.70 per common share. The Common Shares issued to Co. was subject to a four-month statutory hold period which expires Mar. 14, 2019. Additionally, under the Private Placement purchase agreement, Co. agreed that until May 14, 2019 it would not cause or permit any transfer of any Common Shares.

TRAVELZOO

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	84,260,000	79,527,000
Cost & expenses	78,811,000	76,061,000
Operating income	5,449,000	3,466,000
Other income (expense), net	100,000	111,000
Net before taxes	5,549,000	3,577,000
Income taxes	2,452,000	2,660,000
Income contin. oper.		917,000
Net income	3,097,000	2,855,000
Earnings common share		
Primary	\$0.25	\$0.22
Fully Diluted	\$0.25	\$0.22
Common Shares:		
Full Diluted	12,630,000	13,040,000
Year-end	12,244,000	12,465,000

UHF LOGISTICS GROUP INC**Annual Report**

Consolidated Income Statement, Years Ended Feb. 28 (\$):

	2018	2017
Amortization expense		817
Bank charges & interest expense		374
Filing & transfer agent fees		4,000
Management fees		22,500

	2018	2017
Office expense		
Professional services expense	4,587	4,586
Travel & promotion expense		
Total expenses	4,587	4,586
Income (loss) from operations	(4,587)	(4,586)
Impairment of loan receivable		
Net income (loss)	(4,587)	(4,586)
Weighted average shares outstanding - basic	58,816,666	58,816,666
Weighted average shares outstanding - diluted	58,816,666	58,816,666
Year end shares outstanding	58,816,666	58,816,666
Net income (loss) per share - basic	\$0.00	\$0.00
Net income (loss) per share - diluted	\$0.00	\$0.00
Total number of employees		2
Number of common stockholders		29

As reported from the February 28, 2018 Annual Report

Consolidated Balance Sheet, Years Ended Feb. 28 (\$):

	2018	2017
Accounts payable	9,173	4,586
Total current liabilities	9,173	4,586
Total liabilities	9,173	4,586
Common stock	58,817	58,817
Additional paid in capital	6,261,967	6,261,967
Retained earnings (accumulated deficit)	(6,329,957)	(6,325,370)
Total stockholders' equity (deficit)	(9,173)	(4,586)

As reported from the February 28, 2018 Annual Report

Recent Dividends:

1. UHF Logistics Group Inc common.

No dividends paid.

Annual Dividends:

1. UHF Logistics Group Inc common.

No dividends paid.

UNITED STATES LIME & MINERALS INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	109,801	109,605
Cost & expenses	93,787	90,572
Operating income	16,014	19,033
Interest expense	191	174
Other income (expense), net	1,307	665
Net before taxes	17,130	19,524
Income taxes	1,676	3,959
Net income	15,454	15,565
Earnings common share		
Primary	\$2.76	\$2.79
Fully Diluted	\$2.76	\$2.79
Common Shares:		
Full Diluted	5,602	5,586
Year-end	5,598	5,577

UNIVERSAL DISPLAY CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	177,271,000	219,762,000
Cost & expenses	119,330,000	114,910,000
Operating income	41,462,000	88,367,000
Other income (expense), net	(66,000)	(7,000)
Net before taxes	46,551,000	90,688,000
Income taxes	6,960,000	19,616,000
Net income	39,591,000	71,072,000
Balance for common	39,110,000	69,923,000
Earnings common share		
Primary	\$0.83	\$1.50
Fully Diluted	\$0.83	\$1.49

	2018	2017
Common Shares:		
Full Diluted	46,893,768	46,793,429
Year-end	47,310,901	47,108,224

VEECO INSTRUMENTS INC (DE)

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	443,110	336,025
Cost & expenses	691,529	371,186
Operating income	(276,521)	(56,883)
Interest income	2,266	1,932
Interest expense	16,113	14,301
Net before taxes	(290,368)	(69,252)
Income taxes	(27,954)	(26,334)
Net income	(262,414)	(42,918)
Earnings common share		
Primary	\$(5.55)	\$(1.00)
Fully Diluted	\$(5.55)	\$(1.00)
Common Shares:		
Full Diluted	47,283	43,100
Year-end	47,793	48,294

VERITEX HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	74,887	36,823
Operating income	36,825	17,697
Net before taxes	36,825	17,697
Income taxes	7,309	5,802
Net income	29,516	11,895
Balance for common	29,516	11,853
Earnings common share		
Primary	\$1.22	\$0.70
Fully Diluted	\$1.20	\$0.69
Common Shares:		
Full Diluted	24,587	17,232
Year-end	24,192	22,644

VIVUS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	44,948	53,432
Cost & expenses	45,182	48,306
Operating income	(5,236)	4,673
Other income (expense), net	(27,162)	(25,112)
Net before taxes	(32,398)	(20,439)
Income taxes	52	(3)
Net income	(32,450)	(20,436)
Earnings common share		
Primary	\$(3.06)	\$(1.93)
Fully Diluted	\$(3.06)	\$(1.93)
Common Shares:		
Full Diluted	10,617	10,567
Year-end	10,628	10,586

WEIGHT WATCHERS INTERNATIONAL INC

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	1,183,735	994,422
Cost & expenses	875,097	776,605
Operating income	308,638	217,817
Interest expense	107,238	82,227
Other income (expense), net	(1,978)	1,276
Net before taxes	199,422	136,866
Income taxes	19,580	36,457
Net income	179,842	100,409
Earnings common share		
Primary	\$2.72	\$1.57
Fully Diluted	\$2.57	\$1.48
Common Shares:		
Full Diluted	70,117	67,939
Year-end	66,836	64,525

WERNER ENTERPRISES, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,811,549	1,549,372
Cost & expenses	1,491,826	1,287,994
Operating income	149,284	98,759
Interest income	2,079	2,556
Interest expense	1,842	1,892
Other income (expense), net	(172)	(293)
Net before taxes	149,349	99,130
Income taxes	35,764	37,375

Net income	113,585	61,755
Earnings common share		
Primary	\$1.58	\$0.85
Fully Diluted	\$1.57	\$0.85
Common Shares:		
Full Diluted.....	72,300	72,517
Year-end	71,194

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2018 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.